

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 1
JANUARY 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 1

January 2016

CONTENTS

| | <i>PAGE</i> |
|---|-------------|
| 1.0 INTRODUCTION..... | iii |
| 1.1 How to use the Cumulative Supplement..... | iii |
| 1.2 Cumulative Supplement Content | iv |
| 1.3 Applicant Name Changes | v |
| 1.4 Levothyroxine Sodium..... | v |
| 1.5 Availability of the Edition | vi |
| 1.6 Report of Counts for the Prescription Drug Product List..... | vii |
| 1.7 Cumulative Supplement Legend..... | viii |
| | |
| DRUG PRODUCT LISTS | |
| Prescription Drug Product List | 1-1 |
| OTC Drug Product List | 2-1 |
| Drug Products with Approval under Section 505 of the Act | |
| Administered by the Center for Biologics Evaluation and Research List | 3-1 |
| Orphan Product Designations and Approvals List | 4-1 |
| Drug Products Which Must Demonstrate in vivo Bioavailability | |
| Only if Product Fails to Achieve Adequate Dissolution | 5-1 |
| | |
| PATENT AND EXCLUSIVITY INFORMATION ADDENDUM | |
| A. Patent and Exclusivity Lists | A-1 |
| B. Patent and Exclusivity Terms | B-1 |

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

36th EDITION

CUMULATIVE SUPPLEMENT 01
January 2016

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 35th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

| | |
|--|---|
| FORMER APPLICANT NAME | NEW APPLICANT NAME |
| <u> (FORMER ABBREVIATED NAME) </u> | <u> (NEW ABBREVIATED NAME) </u> |

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

| Trade Name | Applicant | Potency | TE Code | Appl No | Product No |
|----------------------|-------------|---------|---------|---------|------------|
| UNITHROID | STEVENS J | 0.025MG | AB1 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB1 | 76187 | 001 |
| LEVOXYL | KING PHARMS | 0.025MG | AB1 | 21301 | 001 |
| SYNTHROID | ABBOTT | 0.025MG | AB1 | 21402 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB1 | 21342 | 001 |
| | | | | | |
| SYNTHROID | ABBOTT | 0.025MG | AB2 | 21402 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB2 | 76187 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB2 | 21342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB2 | 21210 | 001 |
| | | | | | |
| LEVOXYL | KUNG PHARMS | 0.025MG | AB3 | 21301 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB3 | 21342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB3 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB3 | 76187 | 001 |
| | | | | | |
| LEVOTHROID | LLOYD | 0.025MG | AB4 | 21116 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB4 | 76187 | 001 |
| | | | | | |

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

| <u>CATEGORIES COUNTED</u> | <u>DEC 2015</u> | <u>MAR 2016</u> | <u>JUN 2016</u> | <u>SEPT 2016</u> | <u>DEC 2016</u> |
|------------------------------------|------------------|-----------------|-----------------|------------------|-----------------|
| DRUG PRODUCTS LISTED | 17151 | | | | |
| SINGLE SOURCE | 2664 (15.5%) | | | | |
| MULTISOURCE | 14487 (84.5%) | | | | |
| THERAPEUTICALLY EQUIVALENT | 14366 (83.8%) | | | | |
| NOT THERAPEUTICALLY EQUIVALENT | 121 (0.7%) | | | | |
| EXCEPTIONS ¹ | 73 (0.4%) | | | | |
| NEW MOLECULAR ENTITIES APPROVED | 28 | | | | |
| NUMBER OF APPLICANTS | 1011 | | | | |

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

| | |
|------|---|
| NEWA | New drug product approval usually in the supplement month. |
| CAHN | Applicant holder firm name has changed. |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |
| CDFR | Change. Dosage Form; Route of Administration. |
| CFTG | Change. A first time generic for the innovator product. A TE Code is added. |
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug. |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition. |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

| | | | | | | | |
|-----|---|-------------------|-----------------|----------|-----|--------------|----------|
| >A> | @ | INGENUS PHARMS NJ | 325MG;50MG;40MG | A 040864 | 001 | Dec 01, 2008 | Jan CAHN |
| >D> | @ | MIRROR PHARMS | 325MG;50MG;40MG | A 040864 | 001 | Dec 01, 2008 | Jan CAHN |
| >D> | @ | MUTUAL PHARM | 325MG;50MG;40MG | A 040601 | 001 | Jul 29, 2005 | Jan CAHN |
| >A> | @ | SUN PHARM INDS | 325MG;50MG;40MG | A 040601 | 001 | Jul 29, 2005 | Jan CAHN |

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

| | | | | | | | |
|-----|----|---------------|-------------|----------|-----|--------------|----------|
| >D> | AA | ALVOGEN INC | 325MG;7.5MG | A 202677 | 001 | Jul 26, 2012 | Jan CAHN |
| >D> | AA | | 325MG;10MG | A 202677 | 002 | Jul 26, 2012 | Jan CAHN |
| >A> | AA | ALVOGEN MALTA | 325MG;7.5MG | A 202677 | 001 | Jul 26, 2012 | Jan CAHN |
| >A> | AA | | 325MG;10MG | A 202677 | 002 | Jul 26, 2012 | Jan CAHN |

ACETYLCYSTEINE

>A> TABLET, EFFERVESCENT;ORAL

>A> CETYLEV

| | | | | | | | |
|-----|---|------------------|-------|----------|-----|--------------|----------|
| >A> | | ARBOR PHARMS LLC | 500MG | N 207916 | 001 | Jan 29, 2016 | Jan NEWA |
| >A> | + | | 2.5MG | N 207916 | 002 | Jan 29, 2016 | Jan NEWA |

ACYCLOVIR

TABLET;BUCCAL

SITAVIG

| | | | | | | | |
|-----|---|--------------------|------|----------|-----|--------------|----------|
| >A> | + | CIPHER PHARMS US | 50MG | N 203791 | 001 | Apr 12, 2013 | Jan CAHN |
| >D> | + | INNOCUTIS HOLDINGS | 50MG | N 203791 | 001 | Apr 12, 2013 | Jan CAHN |

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

| | | | | | | | |
|-----|----|------------------|------|----------|-----|--------------|----------|
| >A> | AB | UNICHEM LABS LTD | 10MG | A 203192 | 001 | Jan 28, 2016 | Jan NEWA |
|-----|----|------------------|------|----------|-----|--------------|----------|

ALLOPURINOL

TABLET;ORAL

ZYLOPRIM

| | | | | | | | |
|-----|----|--------------------|-------|----------|-----|--|----------|
| >D> | AB | PROMETHEUS LABS | 100MG | N 016084 | 001 | | Jan CAHN |
| >D> | AB | + | 300MG | N 016084 | 002 | | Jan CAHN |
| >A> | AB | SEBELA IRELAND LTD | 100MG | N 016084 | 001 | | Jan CAHN |
| >A> | AB | + | 300MG | N 016084 | 002 | | Jan CAHN |

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

| | | | | | | | |
|-----|----|---------------------|-------|----------|-----|--------------|----------|
| >D> | AB | ACTAVIS LABS FL INC | 0.5MG | A 077198 | 001 | May 13, 2010 | Jan DISC |
| >A> | | @ | 0.5MG | A 077198 | 001 | May 13, 2010 | Jan DISC |
| >D> | AB | | 1MG | A 077198 | 002 | May 13, 2010 | Jan DISC |
| >A> | | @ | 1MG | A 077198 | 002 | May 13, 2010 | Jan DISC |
| >D> | AB | | 2MG | A 077198 | 003 | May 13, 2010 | Jan DISC |
| >A> | | @ | 2MG | A 077198 | 003 | May 13, 2010 | Jan DISC |
| >D> | AB | | 3MG | A 077198 | 004 | May 13, 2010 | Jan DISC |
| >A> | | @ | 3MG | A 077198 | 004 | May 13, 2010 | Jan DISC |
| >D> | AB | IMPAX LABS | 0.5MG | A 077968 | 004 | May 24, 2007 | Jan DISC |
| >A> | | @ | 0.5MG | A 077968 | 004 | May 24, 2007 | Jan DISC |
| >D> | AB | | 1MG | A 077968 | 003 | May 24, 2007 | Jan DISC |
| >A> | | @ | 1MG | A 077968 | 003 | May 24, 2007 | Jan DISC |
| >D> | AB | | 2MG | A 077968 | 002 | May 24, 2007 | Jan DISC |
| >A> | | @ | 2MG | A 077968 | 002 | May 24, 2007 | Jan DISC |
| >D> | AB | | 3MG | A 077968 | 001 | May 24, 2007 | Jan DISC |
| >A> | | @ | 3MG | A 077968 | 001 | May 24, 2007 | Jan DISC |

ALPROSTADIL

SUPPOSITORY;URETHRAL

MUSE

| | | | | | | | |
|-----|---|-------------|---------|----------|-----|--------------|----------|
| >D> | | MEDA PHARMS | 0.125MG | N 020700 | 001 | Nov 19, 1996 | Jan CRLD |
| >A> | + | | 0.125MG | N 020700 | 001 | Nov 19, 1996 | Jan CRLD |
| >D> | | | 0.25MG | N 020700 | 002 | Nov 19, 1996 | Jan CRLD |
| >A> | + | | 0.25MG | N 020700 | 002 | Nov 19, 1996 | Jan CRLD |
| >D> | | | 0.5MG | N 020700 | 003 | Nov 19, 1996 | Jan CRLD |
| >A> | + | | 0.5MG | N 020700 | 003 | Nov 19, 1996 | Jan CRLD |

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

| | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|----------|
| >D> | AB | BANNER LIFE SCIENCES | 100MG | A078720 | 001 | May 29, 2008 | Jan CAHN |
| >A> | AB | BIONPHARMA INC | 100MG | A078720 | 001 | May 29, 2008 | Jan CAHN |

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

| | | | | | | | |
|-----|----|-----------------|------------------------------------|---------|-----|--------------|----------|
| >A> | AP | MA GENERAL HOSP | 30mCi-300mCi/8ML (3.75-37.5mCi/ML) | A207025 | 001 | Feb 03, 2016 | Jan NEWA |
| >A> | AP | MIDWEST MEDCL | 30mCi-300mCi/8ML (3.75-37.5mCi/ML) | A204457 | 001 | Nov 18, 2015 | Jan NEWA |

AMOXICILLIN

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

| | | | | | | | |
|-----|---|----------------------|-------|---------|-----|--------------|----------|
| >D> | + | PRAGMA PHARMS LLC | 775MG | N050813 | 001 | Jan 23, 2008 | Jan CAHN |
| >A> | + | VERNALIS R AND D LTD | 775MG | N050813 | 001 | Jan 23, 2008 | Jan CAHN |

AMPHETAMINE

>A> TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

>A> ADZENYS XR-ODT

| | | | | | | | |
|-----|--|--------------|----------------|---------|-----|--------------|----------|
| >A> | | NEOS THERAPS | EQ 3.1MG BASE | N204326 | 001 | Jan 27, 2016 | Jan NEWA |
| >A> | | | EQ 6.3MG BASE | N204326 | 002 | Jan 27, 2016 | Jan NEWA |
| >A> | | | EQ 9.4MG BASE | N204326 | 003 | Jan 27, 2016 | Jan NEWA |
| >A> | | | EQ 12.5MG BASE | N204326 | 004 | Jan 27, 2016 | Jan NEWA |
| >A> | | | EQ 15.7MG BASE | N204326 | 005 | Jan 27, 2016 | Jan NEWA |
| >A> | | | EQ 18.8MG BASE | N204326 | 006 | Jan 27, 2016 | Jan NEWA |

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

| | | | | | | | |
|-----|----|-------------------|---------------------------------|---------|-----|--------------|----------|
| >A> | AB | ACTAVIS ELIZABETH | 1.25MG;1.25MG;1.25MG;1.25MG | A206340 | 001 | Feb 05, 2016 | Jan NEWA |
| >A> | AB | | 1.875MG;1.875MG;1.875MG;1.875MG | A206340 | 002 | Feb 05, 2016 | Jan NEWA |
| >A> | AB | | 2.5MG;2.5MG;2.5MG;2.5MG | A206340 | 003 | Feb 05, 2016 | Jan NEWA |
| >A> | AB | | 3.125MG;3.125MG;3.125MG;3.125MG | A206340 | 004 | Feb 05, 2016 | Jan NEWA |
| >A> | AB | | 3.75MG;3.75MG;3.75MG;3.75MG | A206340 | 005 | Feb 05, 2016 | Jan NEWA |
| >A> | AB | | 5MG;5MG;5MG;5MG | A206340 | 006 | Feb 05, 2016 | Jan NEWA |
| >A> | AB | | 7.5MG;7.5MG;7.5MG;7.5MG | A206340 | 007 | Feb 05, 2016 | Jan NEWA |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

| | | | | | | | |
|-----|--|-----------------------|--|---------|-----|--------------|----------|
| >D> | | @ IGI LABS INC | 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL | N018933 | 002 | Aug 08, 1985 | Jan CAHN |
| >A> | | @ TELIGENT PHARMA INC | 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL | N018933 | 002 | Aug 08, 1985 | Jan CAHN |

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

| | | | | | | | |
|-----|--|--------------------|-----------------|---------|-----|--------------|----------|
| >D> | | @ MUTUAL PHARM | 325MG;50MG;40MG | A078149 | 001 | Jun 13, 2007 | Jan CAHN |
| >A> | | @ NOSTRUM LABS INC | 325MG;50MG;40MG | A078149 | 001 | Jun 13, 2007 | Jan CAHN |

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

| | | | | | | | |
|-----|----|-------------------|-------------|---------|-----|--------------|----------|
| >A> | AB | INGENUS PHARMS NJ | 325MG;200MG | A040832 | 001 | Jan 07, 2010 | Jan CAHN |
| >D> | AB | MIRROR PHARMS | 325MG;200MG | A040832 | 001 | Jan 07, 2010 | Jan CAHN |

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

| | | | | | | | |
|-----|----|---------------------|------------------|---------|-----|--------------|----------|
| >A> | | @ INGENUS PHARMS NJ | 325MG;200MG;16MG | A040860 | 001 | Jan 07, 2010 | Jan CAHN |
| >D> | | @ MIRROR PHARMS | 325MG;200MG;16MG | A040860 | 001 | Jan 07, 2010 | Jan CAHN |
| >D> | AB | SANDOZ | 325MG;200MG;16MG | A040118 | 001 | Apr 16, 1996 | Jan CRLD |

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

| | | | | | | | | |
|-----|----|--------------------------|------------------------------|---------|-----|--------------|-----|------|
| >A> | + | | 325MG;200MG;16MG | A040118 | 001 | Apr 16, 1996 | Jan | CRLD |
| >D> | | SOMA COMPOUND W/ CODEINE | | | | | | |
| >D> | AB | + | MEDA PHARMS 325MG;200MG;16MG | N012366 | 002 | Jul 11, 1983 | Jan | DISC |
| >A> | | @ | 325MG;200MG;16MG | N012366 | 002 | Jul 11, 1983 | Jan | DISC |

ATENOLOL

TABLET;ORAL

ATENOLOL

| | | | | | | | | |
|-----|----|--|------------------------|---------|-----|--------------|-----|------|
| >D> | AB | | ALVOGEN IPCO SARL 25MG | A073646 | 001 | Jul 31, 1992 | Jan | CAHN |
| >D> | AB | | 50MG | A072303 | 001 | Jul 15, 1988 | Jan | CAHN |
| >D> | AB | | 100MG | A072304 | 001 | Jul 15, 1988 | Jan | CAHN |
| >A> | AB | | ALVOGEN MALTA 25MG | A073646 | 001 | Jul 31, 1992 | Jan | CAHN |
| >A> | AB | | 50MG | A072303 | 001 | Jul 15, 1988 | Jan | CAHN |
| >A> | AB | | 100MG | A072304 | 001 | Jul 15, 1988 | Jan | CAHN |

TENORMIN

| | | | | | | | | |
|-----|----|---|------------------------|---------|-----|--------------|-----|------|
| >D> | AB | | ALVOGEN IPCO SARL 25MG | N018240 | 004 | Apr 09, 1990 | Jan | CAHN |
| >D> | AB | | 50MG | N018240 | 001 | | Jan | CAHN |
| >D> | AB | + | 100MG | N018240 | 002 | | Jan | CAHN |
| >A> | AB | | ALVOGEN MALTA 25MG | N018240 | 004 | Apr 09, 1990 | Jan | CAHN |
| >A> | AB | | 50MG | N018240 | 001 | | Jan | CAHN |
| >A> | AB | + | 100MG | N018240 | 002 | | Jan | CAHN |

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

| | | | | | | | | |
|-----|----|--|-----------------------------|---------|-----|--------------|-----|------|
| >D> | AB | | ALVOGEN IPCO SARL 50MG;25MG | A072301 | 001 | May 31, 1990 | Jan | CAHN |
| >D> | AB | | 100MG;25MG | A072302 | 001 | May 31, 1990 | Jan | CAHN |
| >A> | AB | | ALVOGEN MALTA 50MG;25MG | A072301 | 001 | May 31, 1990 | Jan | CAHN |
| >A> | AB | | 100MG;25MG | A072302 | 001 | May 31, 1990 | Jan | CAHN |

TENORETIC 100

| | | | | | | | | |
|-----|----|---|------------------------------|---------|-----|--------------|-----|------|
| >D> | AB | + | ALVOGEN IPCO SARL 100MG;25MG | N018760 | 001 | Jun 08, 1984 | Jan | CAHN |
| >A> | AB | + | ALVOGEN MALTA 100MG;25MG | N018760 | 001 | Jun 08, 1984 | Jan | CAHN |

TENORETIC 50

| | | | | | | | | |
|-----|----|--|-----------------------------|---------|-----|--------------|-----|------|
| >D> | AB | | ALVOGEN IPCO SARL 50MG;25MG | N018760 | 002 | Jun 08, 1984 | Jan | CAHN |
| >A> | AB | | ALVOGEN MALTA 50MG;25MG | N018760 | 002 | Jun 08, 1984 | Jan | CAHN |

AURANOFIN

CAPSULE;ORAL

RIDAURA

| | | | | | | | | |
|-----|---|--------------------|-----|---------|-----|--------------|-----|------|
| >D> | + | PROMETHEUS LABS | 3MG | N018689 | 001 | May 24, 1985 | Jan | CAHN |
| >A> | + | SEBELA IRELAND LTD | 3MG | N018689 | 001 | May 24, 1985 | Jan | CAHN |

AZATHIOPRINE

TABLET;ORAL

IMURAN

| | | | | | | | | |
|-----|----|--------------------|------|---------|-----|--|-----|------|
| >D> | @ | PROMETHEUS LABS | 25MG | N016324 | 002 | | Jan | CAHN |
| >D> | AB | + | 50MG | N016324 | 001 | | Jan | CAHN |
| >A> | @ | SEBELA IRELAND LTD | 25MG | N016324 | 002 | | Jan | CAHN |
| >A> | AB | + | 50MG | N016324 | 001 | | Jan | CAHN |

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

| | | | | | | | | |
|-----|---|--------------------|--------------------|---------|-----|--|-----|------|
| >D> | @ | PROMETHEUS LABS | EQ 100MG BASE/VIAL | N017391 | 001 | | Jan | CAHN |
| >A> | @ | SEBELA IRELAND LTD | EQ 100MG BASE/VIAL | N017391 | 001 | | Jan | CAHN |

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

| | | | | | | | | |
|-----|---|----------------------|-------------------|---------|-----|--------------|-----|------|
| >D> | | ARBOR PHARMS IRELAND | EQ 40MG MEDOXOMIL | N200796 | 001 | Feb 25, 2011 | Jan | CAHN |
| >D> | + | | EQ 80MG MEDOXOMIL | N200796 | 002 | Feb 25, 2011 | Jan | CAHN |
| >A> | | ARBOR PHARMS LLC | EQ 40MG MEDOXOMIL | N200796 | 001 | Feb 25, 2011 | Jan | CAHN |
| >A> | + | | EQ 80MG MEDOXOMIL | N200796 | 002 | Feb 25, 2011 | Jan | CAHN |

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOL

| | | | | | | | | |
|-----|---|----------------------|--------------------------|---------|-----|--------------|-----|------|
| >D> | | ARBOR PHARMS IRELAND | EQ 40MG MEDOXOMIL;12.5MG | N202331 | 001 | Dec 20, 2011 | Jan | CAHN |
| >D> | + | | EQ 40MG MEDOXOMIL;25MG | N202331 | 002 | Dec 20, 2011 | Jan | CAHN |
| >A> | | ARBOR PHARMS LLC | EQ 40MG MEDOXOMIL;12.5MG | N202331 | 001 | Dec 20, 2011 | Jan | CAHN |

TABLET;ORAL
EDARBYCLOR
>A> + EQ 40MG MEDOXOMIL;25MG N202331 002 Dec 20, 2011 Jan CAHN

BACLOFEN

TABLET;ORAL
BACLOFEN
>A> AB NORTHSTAR HLTHCARE 10MG A078401 002 Sep 18, 2009 Jan NEWA

BARIUM SULFATE

FOR SUSPENSION;ORAL
E-Z-HD
>A> + BRACCO 334GM/BOTTLE N208036 001 Jan 11, 2016 Jan NEWA
SUSPENSION;ORAL
READI-CAT 2
>A> + BRACCO 2% (9GM/450ML) N208143 001 Jan 15, 2016 Jan NEWA
>A> READI-CAT 2 SMOOTHIES
>A> BRACCO 2% (9GM/450ML) N208143 002 Jan 15, 2016 Jan NEWA

BENZAEPRIIL HYDROCHLORIDE

TABLET;ORAL
BENZAEPRIIL HYDROCHLORIDE
>D> AB ACTAVIS LABS FL INC 5MG A076267 001 Feb 11, 2004 Jan DISC
>A> @ 5MG A076267 001 Feb 11, 2004 Jan DISC
>D> AB 10MG A076267 002 Feb 11, 2004 Jan DISC
>A> @ 10MG A076267 002 Feb 11, 2004 Jan DISC
>D> AB 20MG A076267 003 Feb 11, 2004 Jan DISC
>A> @ 20MG A076267 003 Feb 11, 2004 Jan DISC
>D> AB 40MG A076267 004 Feb 11, 2004 Jan DISC
>A> @ 40MG A076267 004 Feb 11, 2004 Jan DISC

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
>D> AB ACTAVIS LABS FL INC 5MG;6.25MG A076342 001 Feb 11, 2004 Jan DISC
>A> @ 5MG;6.25MG A076342 001 Feb 11, 2004 Jan DISC
>D> AB 10MG;12.5MG A076342 002 Feb 11, 2004 Jan DISC
>A> @ 10MG;12.5MG A076342 002 Feb 11, 2004 Jan DISC
>D> AB 20MG;12.5MG A076342 003 Feb 11, 2004 Jan DISC
>A> @ 20MG;12.5MG A076342 003 Feb 11, 2004 Jan DISC
>D> AB 20MG;25MG A076342 004 Feb 11, 2004 Jan DISC
>A> @ 20MG;25MG A076342 004 Feb 11, 2004 Jan DISC

BENZONATATE

CAPSULE;ORAL
BENZONATATE
>D> AA BANNER LIFE SCIENCES 100MG A081297 001 Jan 29, 1993 Jan CAHN
>D> AA 200MG A081297 002 Oct 30, 2007 Jan CAHN
>A> AA BIONPHARMA INC 100MG A081297 001 Jan 29, 1993 Jan CAHN
>A> AA 200MG A081297 002 Oct 30, 2007 Jan CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE
>D> AT IGI LABS INC EQ 0.5% BASE A075630 001 Apr 12, 2001 Jan CAHN
>A> AT TELIGENT PHARMA INC EQ 0.5% BASE A075630 001 Apr 12, 2001 Jan CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL
HELIDAC
>D> @ PROMETHEUS LABS 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N050719 001 Aug 15, 1996 Jan CAHN
N/A,500MG
>A> @ SEBELA IRELAND LTD 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N050719 001 Aug 15, 1996 Jan CAHN
N/A,500MG

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL
BROMOCRIPTINE MESYLATE
>D> AB MYLAN EQ 5MG BASE A077226 001 Apr 04, 2005 Jan CRLD
>A> AB + EQ 5MG BASE A077226 001 Apr 04, 2005 Jan CRLD
>D> PARLODEL
>D> AB + US PHARMS HOLDINGS I EQ 5MG BASE N017962 002 Mar 01, 1982 Jan DISC

CAPSULE;ORAL
 PARLODEL
 >A> @ EQ 5MG BASE N017962 002 Mar 01, 1982 Jan DISC
 TABLET;ORAL
 BROMOCRIPTINE MESYLATE
 >D> AB PADDOCK LLC EQ 2.5MG BASE A077646 001 Oct 01, 2008 Jan CRLD
 >A> AB + EQ 2.5MG BASE A077646 001 Oct 01, 2008 Jan CRLD
 >D> PARLODEL
 >D> AB + US PHARMS HOLDINGS I EQ 2.5MG BASE N017962 001 Jan DISC
 >A> @ EQ 2.5MG BASE N017962 001 Jan DISC

BUDESONIDE

CAPSULE;ORAL
 ENTOCORT EC
 >D> AB + ASTRAZENECA 3MG N021324 001 Oct 02, 2001 Jan CAHN
 >A> AB + ELAN PHARMA INTL LTD 3MG N021324 001 Oct 02, 2001 Jan CAHN

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL
 BUPRENORPHINE HYDROCHLORIDE
 >A> AB SUN PHARM INDS LTD EQ 2MG BASE A201760 001 Jan 29, 2016 Jan NEWA
 >A> AB EQ 8MG BASE A201760 002 Jan 29, 2016 Jan NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
 BUPROPION HYDROCHLORIDE
 >A> AB1 INVAGEN PHARMS 100MG A206674 001 Feb 09, 2016 Jan NEWA
 >A> AB1 150MG A206674 002 Feb 09, 2016 Jan NEWA
 >A> AB1 200MG A206674 003 Feb 09, 2016 Jan NEWA

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION
 BUTORPHANOL TARTRATE
 >D> @ APOTEX INC 2MG/ML A075697 001 Oct 23, 2001 Jan CAHN
 >A> @ CLARIS 2MG/ML A075697 001 Oct 23, 2001 Jan CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL
 MIGERGOT
 >D> + CREALTA PHARMS LLC 100MG;2MG A086557 001 Oct 04, 1983 Jan CAHN
 >A> + HORIZON PHARMA 100MG;2MG A086557 001 Oct 04, 1983 Jan CAHN

CALCITRIOL

CAPSULE;ORAL
 CALCITRIOL
 >D> AB BANNER LIFE SCIENCES 0.25MCG A091174 001 May 24, 2013 Jan CAHN
 >D> AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN
 >A> AB BIONPHARMA INC 0.25MCG A091174 001 May 24, 2013 Jan CAHN
 >A> AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN

CAPTOPRIL

TABLET;ORAL
 CAPTOPRIL
 >D> AB SANDOZ 12.5MG A074363 001 Nov 09, 1995 Jan DISC
 >A> @ 12.5MG A074363 001 Nov 09, 1995 Jan DISC
 >D> AB 25MG A074363 002 Nov 09, 1995 Jan DISC
 >A> @ 25MG A074363 002 Nov 09, 1995 Jan DISC
 >D> AB 50MG A074363 003 Nov 09, 1995 Jan DISC
 >A> @ 50MG A074363 003 Nov 09, 1995 Jan DISC
 >D> AB 100MG A074363 004 Nov 09, 1995 Jan DISC
 >A> @ 100MG A074363 004 Nov 09, 1995 Jan DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL
 CARBAMAZEPINE
 >A> AB MYLAN IRELAND LTD 100MG A076697 001 May 20, 2011 Jan CAHN
 >A> AB 200MG A076697 002 May 20, 2011 Jan CAHN
 >A> AB 300MG A076697 003 May 20, 2011 Jan CAHN
 >D> AB MYLAN PHARMS INC 100MG A076697 001 May 20, 2011 Jan CAHN
 >D> AB 200MG A076697 002 May 20, 2011 Jan CAHN
 >D> AB 300MG A076697 003 May 20, 2011 Jan CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

| | | | | | | | | |
|-----|----|-------------------|-------|---------|-----|--------------|-----|------|
| >A> | AA | INGENUS PHARMS NJ | 350MG | A040823 | 001 | Oct 22, 2008 | Jan | CAHN |
| >D> | AA | MIRROR PHARMS | 350MG | A040823 | 001 | Oct 22, 2008 | Jan | CAHN |

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

| | | | | | | | | |
|-----|----|-------------|------------------|---------|-----|--------------|-----|------|
| >A> | AP | HOSPIRA INC | EQ 1GM BASE/VIAL | A201654 | 001 | Feb 03, 2016 | Jan | NEWA |
|-----|----|-------------|------------------|---------|-----|--------------|-----|------|

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------------|--------------------|---------|-----|--------------|-----|------|
| >A> | AP | QILU PHARM CO LTD | EQ 500MG BASE/VIAL | A203704 | 001 | Feb 01, 2016 | Jan | NEWA |
| >A> | AP | | EQ 1GM BASE/VIAL | A203704 | 002 | Feb 01, 2016 | Jan | NEWA |
| >A> | AP | | EQ 2GM BASE/VIAL | A203704 | 003 | Feb 01, 2016 | Jan | NEWA |

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

| | | | | | | | | |
|-----|----|---|--------------------|---------|-----|--------------|-----|------|
| >D> | AP | + SANOFI AVENTIS US | EQ 500MG BASE/VIAL | N050547 | 001 | | Jan | CAHN |
| >D> | AP | + | EQ 1GM BASE/VIAL | N050547 | 002 | | Jan | CAHN |
| >D> | AP | + | EQ 2GM BASE/VIAL | N050547 | 003 | | Jan | CAHN |
| >D> | AP | + | EQ 10GM BASE/VIAL | N050547 | 004 | Dec 29, 1983 | Jan | CAHN |
| >A> | AP | + US PHARM HOLDINGS | EQ 500MG BASE/VIAL | N050547 | 001 | | Jan | CAHN |
| >A> | AP | + | EQ 1GM BASE/VIAL | N050547 | 002 | | Jan | CAHN |
| >A> | AP | + | EQ 2GM BASE/VIAL | N050547 | 003 | | Jan | CAHN |
| >A> | AP | + | EQ 10GM BASE/VIAL | N050547 | 004 | Dec 29, 1983 | Jan | CAHN |
| | | CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | | |
| >D> | | + SANOFI AVENTIS US | EQ 20MG BASE/ML | N050596 | 002 | May 20, 1985 | Jan | CAHN |
| >D> | | + | EQ 40MG BASE/ML | N050596 | 004 | May 20, 1985 | Jan | CAHN |
| >A> | | + US PHARM HOLDINGS | EQ 20MG BASE/ML | N050596 | 002 | May 20, 1985 | Jan | CAHN |
| >A> | | + | EQ 40MG BASE/ML | N050596 | 004 | May 20, 1985 | Jan | CAHN |
| | | CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | | |
| >D> | | @ SANOFI AVENTIS US | EQ 20MG BASE/ML | N050596 | 001 | May 20, 1985 | Jan | CAHN |
| >D> | | @ | EQ 40MG BASE/ML | N050596 | 003 | May 20, 1985 | Jan | CAHN |
| >A> | | @ US PHARM HOLDINGS | EQ 20MG BASE/ML | N050596 | 001 | May 20, 1985 | Jan | CAHN |
| >A> | | @ | EQ 40MG BASE/ML | N050596 | 003 | May 20, 1985 | Jan | CAHN |

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

| | | | | | | | | |
|-----|--|-----------------------|-------------------|---------|-----|--------------|-----|------|
| >D> | | @ IGI LABS INC | EQ 1GM BASE/VIAL | A063293 | 001 | Apr 29, 1993 | Jan | CAHN |
| >D> | | @ | EQ 1GM BASE/VIAL | N050588 | 001 | Dec 27, 1985 | Jan | CAHN |
| >D> | | @ | EQ 2GM BASE/VIAL | A063293 | 002 | Apr 29, 1993 | Jan | CAHN |
| >D> | | @ | EQ 2GM BASE/VIAL | N050588 | 002 | Dec 27, 1985 | Jan | CAHN |
| >D> | | @ | EQ 10GM BASE/VIAL | N050588 | 003 | Apr 25, 1988 | Jan | CAHN |
| >A> | | @ TELIGENT PHARMA INC | EQ 1GM BASE/VIAL | A063293 | 001 | Apr 29, 1993 | Jan | CAHN |
| >A> | | @ | EQ 1GM BASE/VIAL | N050588 | 001 | Dec 27, 1985 | Jan | CAHN |
| >A> | | @ | EQ 2GM BASE/VIAL | A063293 | 002 | Apr 29, 1993 | Jan | CAHN |
| >A> | | @ | EQ 2GM BASE/VIAL | N050588 | 002 | Dec 27, 1985 | Jan | CAHN |
| >A> | | @ | EQ 10GM BASE/VIAL | N050588 | 003 | Apr 25, 1988 | Jan | CAHN |

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

| | | | | | | | | |
|-----|----|--|--------------------|---------|-----|--------------|-----|------|
| >D> | AP | + CONCORDIA PHARMS INC | EQ 1.5GM BASE/VIAL | N050558 | 003 | Oct 19, 1983 | Jan | CAHN |
| >D> | AP | + | EQ 7.5GM BASE/VIAL | N050558 | 004 | Oct 23, 1986 | Jan | CAHN |
| >A> | AP | + IGI LABS INC | EQ 1.5GM BASE/VIAL | N050558 | 003 | Oct 19, 1983 | Jan | CAHN |
| >A> | AP | + | EQ 7.5GM BASE/VIAL | N050558 | 004 | Oct 23, 1986 | Jan | CAHN |
| | | ZINACEF IN PLASTIC CONTAINER | | | | | | |
| >D> | | @ CONCORDIA PHARMS INC | EQ 15MG BASE/ML | N050643 | 001 | Apr 28, 1989 | Jan | CAHN |
| >D> | | + | EQ 30MG BASE/ML | N050643 | 002 | Apr 28, 1989 | Jan | CAHN |
| >A> | | @ IGI LABS INC | EQ 15MG BASE/ML | N050643 | 001 | Apr 28, 1989 | Jan | CAHN |
| >A> | | + | EQ 30MG BASE/ML | N050643 | 002 | Apr 28, 1989 | Jan | CAHN |
| | | INJECTABLE; INTRAMUSCULAR, INTRAVENOUS | | | | | | |
| | | ZINACEF | | | | | | |
| >D> | AB | + CONCORDIA PHARMS INC | EQ 750MG BASE/VIAL | N050558 | 002 | Oct 19, 1983 | Jan | CAHN |
| >A> | AB | + IGI LABS INC | EQ 750MG BASE/VIAL | N050558 | 002 | Oct 19, 1983 | Jan | CAHN |

CELECOXIB

CAPSULE;ORAL
CELECOXIB

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | AUROBINDO PHARMA LTD | 50MG | A206827 | 001 | Feb 01, 2016 | Jan | NEWA |
| >A> | AB | | 100MG | A206827 | 002 | Feb 01, 2016 | Jan | NEWA |
| >A> | AB | | 200MG | A206827 | 003 | Feb 01, 2016 | Jan | NEWA |
| >A> | AB | | 400MG | A206827 | 004 | Feb 01, 2016 | Jan | NEWA |

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL
PERIOGARD

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| >A> | AT | COLGATE-PALMOLIVE CO | 0.12% | A203212 | 001 | Jan 28, 2016 | Jan | NEWA |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|

CHLORTHALIDONE

TABLET;ORAL
CHLORTHALIDONE

| | | | | | | | | |
|-----|----|----------------|------|---------|-----|--------------|-----|------|
| >D> | | MYLAN | 25MG | A086831 | 002 | | Jan | CTEC |
| >A> | AB | | 25MG | A086831 | 002 | | Jan | CTEC |
| >A> | AB | SUN PHARM INDS | 25MG | A089286 | 002 | Jul 21, 1986 | Jan | NEWA |

CICLESONIDE

AEROSOL, METERED;INHALATION
ALVESCO

| | | | | | | | | |
|-----|---|-------------|------------|---------|-----|--------------|-----|------|
| >D> | | TAKEDA GMBH | 0.08MG/INH | N021658 | 002 | Jan 10, 2008 | Jan | CRLD |
| >A> | + | | 0.08MG/INH | N021658 | 002 | Jan 10, 2008 | Jan | CRLD |

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CIPROFLOXACIN EXTENDED RELEASE

| | | | | | | | | |
|-----|----|---------------------|-------------------------|---------|-----|--------------|-----|------|
| >D> | AB | ACTAVIS LABS FL INC | 212.6MG;EQ 287.5MG BASE | A077417 | 001 | Nov 30, 2010 | Jan | DISC |
| >A> | | @ | 212.6MG;EQ 287.5MG BASE | A077417 | 001 | Nov 30, 2010 | Jan | DISC |
| >D> | AB | | 425.2MG;EQ 574.9MG BASE | A077809 | 001 | Nov 30, 2010 | Jan | DISC |
| >A> | | @ | 425.2MG;EQ 574.9MG BASE | A077809 | 001 | Nov 30, 2010 | Jan | DISC |

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL
VELTIN

| | | | | | | | | |
|-----|----|-------------------|-------------|---------|-----|--------------|-----|------|
| >A> | BX | + AQUA PHARMS LLC | 1.2%;0.025% | N050803 | 001 | Jul 16, 2010 | Jan | CAHN |
| >D> | BX | + STIEFEL GSK | 1.2%;0.025% | N050803 | 001 | Jul 16, 2010 | Jan | CAHN |

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL
ANAFRANIL

| | | | | | | | | |
|-----|----|------------------|------|---------|-----|--------------|-----|------|
| >D> | AB | MALLINCKRODT LLC | 25MG | N019906 | 001 | Dec 29, 1989 | Jan | CRLD |
| >A> | AB | + | 25MG | N019906 | 001 | Dec 29, 1989 | Jan | CRLD |
| >D> | AB | + | 50MG | N019906 | 002 | Dec 29, 1989 | Jan | CRLD |
| >A> | AB | | 50MG | N019906 | 002 | Dec 29, 1989 | Jan | CRLD |

COLCHICINE; PROBENECID

TABLET;ORAL
PROBENECID AND COLCHICINE

| | | | | | | | | |
|-----|----|-------------------|-------------|---------|-----|--------------|-----|------|
| >A> | AB | INGENUS PHARMS NJ | 0.5MG;500MG | A040618 | 001 | May 13, 2008 | Jan | CAHN |
| >D> | AB | MIRROR PHARMS | 0.5MG;500MG | A040618 | 001 | May 13, 2008 | Jan | CAHN |

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------------|-----|---------|-----|--------------|-----|------|
| >A> | AA | INGENUS PHARMS NJ | 4MG | A205087 | 001 | Sep 23, 2015 | Jan | CAHN |
| >D> | AA | MIRROR PHARMS LLC | 4MG | A205087 | 001 | Sep 23, 2015 | Jan | CAHN |

DALBAVANCIN HYDROCHLORIDE

| | | | | | | | | |
|-----|---|--------------------------|--------------------|---------|-----|--------------|-----|------|
| >D> | | INJECTABLE;IV (INFUSION) | | | | | | |
| >D> | | DALVANCE | | | | | | |
| >D> | + | DURATA THERAPS INTL | EQ 500MG BASE/VIAL | N021883 | 001 | May 23, 2014 | Jan | CDFR |
| >A> | | POWDER;IV (INFUSION) | | | | | | |
| >A> | | DALVANCE | | | | | | |
| >A> | + | DURATA THERAPS INTL | EQ 500MG BASE/VIAL | N021883 | 001 | May 23, 2014 | Jan | CDFR |

DAPTOMYCIN

| | | | | | | | |
|--------|--------------------------|------------|--|---------|-----|--------------|----------|
| >D> | INJECTABLE;IV (INFUSION) | | | | | | |
| >D> | CUBICIN | | | | | | |
| >D> | @ CUBIST | 250MG/VIAL | | N021572 | 001 | Sep 12, 2003 | Jan CDFR |
| >D> AP | + | 500MG/VIAL | | N021572 | 002 | Sep 12, 2003 | Jan CDFR |
| >D> | DAPTOMYCIN | | | | | | |
| >D> AP | HOSPIRA INC | 500MG/VIAL | | A202857 | 001 | Sep 12, 2014 | Jan CDFR |
| >A> | POWDER;INTRAVENOUS | | | | | | |
| >A> | CUBICIN | | | | | | |
| >A> AP | + | 500MG/VIAL | | N021572 | 002 | Sep 12, 2003 | Jan CDFR |
| >A> | DAPTOMYCIN | | | | | | |
| >A> AP | HOSPIRA INC | 500MG/VIAL | | A202857 | 001 | Sep 12, 2014 | Jan CDFR |
| >A> | POWDER;IV (INFUSION) | | | | | | |
| >A> | CUBICIN | | | | | | |
| >A> | @ CUBIST | 250MG/VIAL | | N021572 | 001 | Sep 12, 2003 | Jan CDFR |

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
ENABLEX

| | | | | | | | |
|--------|----------------------|---------------|--|---------|-----|--------------|----------|
| >A> AB | ALLERGAN PHARMS INTL | EQ 7.5MG BASE | | N021513 | 001 | Dec 22, 2004 | Jan CAHN |
| >A> AB | + | EQ 15MG BASE | | N021513 | 002 | Dec 22, 2004 | Jan CAHN |
| >D> AB | WARNER CHILCOTT LLC | EQ 7.5MG BASE | | N021513 | 001 | Dec 22, 2004 | Jan CAHN |
| >D> AB | + | EQ 15MG BASE | | N021513 | 002 | Dec 22, 2004 | Jan CAHN |

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL

| | | | | | | | |
|--------|-------------------|-------|--|---------|-----|--------------|----------|
| >A> | DEFERASIROX | | | | | | |
| >A> AB | ACTAVIS ELIZABETH | 125MG | | A203560 | 001 | Jan 26, 2016 | Jan NEWA |
| >A> AB | | 250MG | | A203560 | 002 | Jan 26, 2016 | Jan NEWA |
| >A> AB | | 500MG | | A203560 | 003 | Jan 26, 2016 | Jan NEWA |
| >A> | EXJADE | | | | | | |
| >D> | NOVARTIS | 125MG | | N021882 | 001 | Nov 02, 2005 | Jan CFTG |
| >A> AB | | 125MG | | N021882 | 001 | Nov 02, 2005 | Jan CFTG |
| >D> | | 250MG | | N021882 | 002 | Nov 02, 2005 | Jan CFTG |
| >A> AB | | 250MG | | N021882 | 002 | Nov 02, 2005 | Jan CFTG |
| >D> | + | 500MG | | N021882 | 003 | Nov 02, 2005 | Jan CFTG |
| >A> AB | + | 500MG | | N021882 | 003 | Nov 02, 2005 | Jan CFTG |

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
NORPRAMIN

| | | | | | | | |
|--------|-------------------|-------|--|---------|-----|--------------|----------|
| >D> AB | SANOFI AVENTIS US | 10MG | | N014399 | 007 | Feb 11, 1982 | Jan CAHN |
| >D> AB | | 25MG | | N014399 | 001 | | Jan CAHN |
| >D> AB | | 50MG | | N014399 | 003 | | Jan CAHN |
| >D> AB | | 75MG | | N014399 | 004 | | Jan CAHN |
| >D> AB | + | 100MG | | N014399 | 005 | | Jan CAHN |
| >D> AB | | 150MG | | N014399 | 006 | | Jan CAHN |
| >A> AB | US PHARM HOLDINGS | 10MG | | N014399 | 007 | Feb 11, 1982 | Jan CAHN |
| >A> AB | | 25MG | | N014399 | 001 | | Jan CAHN |
| >A> AB | | 50MG | | N014399 | 003 | | Jan CAHN |
| >A> AB | | 75MG | | N014399 | 004 | | Jan CAHN |
| >A> AB | + | 100MG | | N014399 | 005 | | Jan CAHN |
| >A> AB | | 150MG | | N014399 | 006 | | Jan CAHN |

DESONIDE

CREAM;TOPICAL
DESONIDE

| | | | | | | | |
|--------|------------------|-------|--|---------|-----|--------------|----------|
| >A> AB | G AND W LABS INC | 0.05% | | A074027 | 001 | Sep 28, 1992 | Jan CAHN |
| >D> AB | TEVA PHARMS | 0.05% | | A074027 | 001 | Sep 28, 1992 | Jan CAHN |

DEXLANSOPRAZOLE

| | | | | | | | |
|-----|---|------|--|---------|-----|--------------|----------|
| >A> | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | | | | | | |
| >A> | DEXILANT SOLUTAB | | | | | | |
| >A> | + | 30MG | | N208056 | 001 | Jan 26, 2016 | Jan NEWA |

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

| | | | | | | | |
|--------|---------------------|--|--|---------|-----|--------------|----------|
| >A> AP | ACCORD HLTHCARE INC | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | | A204023 | 001 | Feb 09, 2016 | Jan NEWA |
|--------|---------------------|--|--|---------|-----|--------------|----------|

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
 DEXTROAMPHETAMINE SULFATE

| | | | | | | | |
|-----|----|------------------|------|---------|-----|--------------|----------|
| >A> | AB | MYLAN PHARMS INC | 5MG | A206735 | 001 | Jan 27, 2016 | Jan NEWA |
| >A> | AB | | 10MG | A206735 | 002 | Jan 27, 2016 | Jan NEWA |
| >A> | AB | | 15MG | A206735 | 003 | Jan 27, 2016 | Jan NEWA |

DIAZEPAM

INJECTABLE;INJECTION
 DIAZEPAM

| | | | | | | | |
|-----|--|----------------------|--------|---------|-----|--------------|----------|
| >A> | | @ EUROHLTH INTL SARL | 5MG/ML | A070313 | 001 | Dec 16, 1985 | Jan CAHN |
| >D> | | @ HIKMA MAPLE | 5MG/ML | A070313 | 001 | Dec 16, 1985 | Jan CAHN |

TABLET;ORAL
 DIAZEPAM

| | | | | | | | |
|-----|--|-----------------|-----|---------|-----|--------------|----------|
| >A> | | DAVA PHARMS INC | 2MG | A070228 | 002 | Sep 26, 1985 | Jan NEWA |
| >A> | | | 5MG | A070228 | 003 | Sep 26, 1985 | Jan NEWA |

DICLOFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
 DICLOFENAC SODIUM

| | | | | | | | |
|-----|----|-------------------|------|---------|-----|--------------|----------|
| >D> | AT | NEXUS PHARMS | 0.1% | A078553 | 001 | Dec 28, 2007 | Jan CAHN |
| >A> | AT | RISING PHARMS INC | 0.1% | A078553 | 001 | Dec 28, 2007 | Jan CAHN |

DICYCLOMINE HYDROCHLORIDE

SYRUP;ORAL

| | | | | | | | |
|-----|----|---------------------|----------|---------|-----|--------------|----------|
| >D> | | BENTYL | | | | | |
| >D> | AA | + APTALIS PHARMA US | 10MG/5ML | N007961 | 002 | Oct 15, 1984 | Jan DISC |
| >A> | | @ | 10MG/5ML | N007961 | 002 | Oct 15, 1984 | Jan DISC |

DICYCLOMINE HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------|----------|---------|-----|--------------|----------|
| >D> | AA | MIKART | 10MG/5ML | A040169 | 001 | Mar 24, 2005 | Jan CRLD |
| >A> | | + | 10MG/5ML | A040169 | 001 | Mar 24, 2005 | Jan CRLD |

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
 DILTIAZEM HYDROCHLORIDE

| | | | | | | | |
|-----|-----|----------------------|-------|---------|-----|--------------|----------|
| >D> | AB2 | ACTAVIS LABS FL INC | 120MG | A074852 | 001 | Oct 10, 1997 | Jan DISC |
| >A> | | @ | 120MG | A074852 | 001 | Oct 10, 1997 | Jan DISC |
| >D> | AB2 | | 180MG | A074852 | 002 | Oct 10, 1997 | Jan DISC |
| >A> | | @ | 180MG | A074852 | 002 | Oct 10, 1997 | Jan DISC |
| >D> | AB2 | | 240MG | A074852 | 003 | Oct 10, 1997 | Jan DISC |
| >A> | | @ | 240MG | A074852 | 003 | Oct 10, 1997 | Jan DISC |
| >D> | AB3 | VALEANT INTL | 120MG | A075116 | 001 | Dec 23, 1999 | Jan CAHN |
| >D> | AB3 | | 180MG | A075116 | 002 | Dec 23, 1999 | Jan CAHN |
| >D> | AB3 | | 240MG | A075116 | 003 | Dec 23, 1999 | Jan CAHN |
| >D> | AB3 | | 300MG | A075116 | 004 | Dec 23, 1999 | Jan CAHN |
| >A> | AB3 | VALEANT PHARMS NORTH | 120MG | A075116 | 001 | Dec 23, 1999 | Jan CAHN |
| >A> | AB3 | | 180MG | A075116 | 002 | Dec 23, 1999 | Jan CAHN |
| >A> | AB3 | | 240MG | A075116 | 003 | Dec 23, 1999 | Jan CAHN |
| >A> | AB3 | | 300MG | A075116 | 004 | Dec 23, 1999 | Jan CAHN |

DINOPROSTONE

INSERT, EXTENDED RELEASE;VAGINAL
 CERVIDIL

| | | | | | | | |
|-----|--|----------------------|------|---------|-----|--------------|----------|
| >D> | | + FERRING CONTROLLED | 10MG | N020411 | 001 | Mar 30, 1995 | Jan CAHN |
| >A> | | + FERRING PHARMS INC | 10MG | N020411 | 001 | Mar 30, 1995 | Jan CAHN |

DISULFIRAM

TABLET;ORAL
 DISULFIRAM

| | | | | | | | |
|-----|----|--------------------|-------|---------|-----|--------------|----------|
| >A> | AB | ALVOGEN MALTA | 250MG | A091681 | 001 | Aug 08, 2013 | Jan CAHN |
| >D> | AB | ALVOGEN PINE BROOK | 250MG | A091681 | 001 | Aug 08, 2013 | Jan CAHN |

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
 DOBUTAMINE HYDROCHLORIDE

| | | | | | | | |
|-----|--|-----------------------|-------------------|---------|-----|--------------|----------|
| >D> | | @ IGI LABS INC | EQ 12.5MG BASE/ML | A074098 | 001 | Feb 21, 1995 | Jan CAHN |
| >A> | | @ TELIGENT PHARMA INC | EQ 12.5MG BASE/ML | A074098 | 001 | Feb 21, 1995 | Jan CAHN |

DOCETAXELSOLUTION;IV (INFUSION)
DOCETAXEL

| | | | | | | |
|-----|----------------|---------------------|---------|-----|--------------|----------|
| >A> | EAGLE PHARMS | 20MG/ML (20MG/ML) | N205934 | 001 | Dec 22, 2015 | Jan CAHN |
| >A> | | 80MG/4ML (20MG/ML) | N205934 | 002 | Dec 22, 2015 | Jan CAHN |
| >A> | | 160MG/8ML (20MG/ML) | N205934 | 003 | Dec 22, 2015 | Jan CAHN |
| >D> | TEIKOKU PHARMA | 20MG/ML (20MG/ML) | N205934 | 001 | Dec 22, 2015 | Jan CAHN |
| >D> | | 80MG/4ML (20MG/ML) | N205934 | 002 | Dec 22, 2015 | Jan CAHN |
| >D> | | 160MG/8ML (20MG/ML) | N205934 | 003 | Dec 22, 2015 | Jan CAHN |

DOLASETRON MESYLATEINJECTABLE;INJECTION
ANZEMET

| | | | | | | |
|-----|---------------------|--------------------------|---------|-----|--------------|----------|
| >D> | + SANOFI AVENTIS US | 12.5MG/0.625ML (20MG/ML) | N020624 | 002 | Sep 11, 1997 | Jan CAHN |
| >D> | + | 100MG/5ML (20MG/ML) | N020624 | 001 | Sep 11, 1997 | Jan CAHN |
| >D> | + | 500MG/25ML (20MG/ML) | N020624 | 003 | Dec 11, 2001 | Jan CAHN |
| >A> | + US PHARM HOLDINGS | 12.5MG/0.625ML (20MG/ML) | N020624 | 002 | Sep 11, 1997 | Jan CAHN |
| >A> | + | 100MG/5ML (20MG/ML) | N020624 | 001 | Sep 11, 1997 | Jan CAHN |
| >A> | + | 500MG/25ML (20MG/ML) | N020624 | 003 | Dec 11, 2001 | Jan CAHN |

TABLET;ORAL

ANZEMET

| | | | | | | |
|-----|-------------------|-------|---------|-----|--------------|----------|
| >D> | SANOFI AVENTIS US | 50MG | N020623 | 001 | Sep 11, 1997 | Jan CAHN |
| >D> | + | 100MG | N020623 | 002 | Sep 11, 1997 | Jan CAHN |
| >A> | US PHARM HOLDINGS | 50MG | N020623 | 001 | Sep 11, 1997 | Jan CAHN |
| >A> | + | 100MG | N020623 | 002 | Sep 11, 1997 | Jan CAHN |

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

| | | | | | | |
|--------|---------------------|------|---------|-----|--------------|----------|
| >A> AB | OSMOTICA PHARM CORP | 23MG | A203114 | 001 | Jan 26, 2016 | Jan NEWA |
|--------|---------------------|------|---------|-----|--------------|----------|

DOXEPIIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIIN HYDROCHLORIDE

| | | | | | | |
|--------|------------------|-------------|---------|-----|--------------|----------|
| >A> AB | MYLAN PHARMS INC | EQ 3MG BASE | A202337 | 001 | Jan 20, 2016 | Jan NEWA |
| >A> AB | | EQ 6MG BASE | A202337 | 002 | Jan 20, 2016 | Jan NEWA |

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

| | | | | | | |
|--------|-----------------|------------|---------|-----|--------------|----------|
| >A> AB | NOVAST LABS LTD | 3MG;0.02MG | A202016 | 001 | Jan 26, 2016 | Jan NEWA |
|--------|-----------------|------------|---------|-----|--------------|----------|

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

| | | | | | | |
|--------|-------------------|-------|---------|-----|--------------|----------|
| >D> AB | BANNER PHARMACAPS | 0.5MG | A200899 | 001 | Nov 20, 2015 | Jan CAHN |
| >A> AB | BIONPHARMA INC | 0.5MG | A200899 | 001 | Nov 20, 2015 | Jan CAHN |

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

| | | | | | | |
|-----|----------------------------|---------|---------|-----|--|----------|
| >D> | @ IGI LABS INC | 10MG/ML | N007959 | 001 | | Jan CAHN |
| >A> | @ TELIGENT PHARMA INC | 10MG/ML | N007959 | 001 | | Jan CAHN |
| | TENSILON PRESERVATIVE FREE | | | | | |
| >D> | @ IGI LABS INC | 10MG/ML | N007959 | 002 | | Jan CAHN |
| >A> | @ TELIGENT PHARMA INC | 10MG/ML | N007959 | 002 | | Jan CAHN |

ELBASVIR; GRAZOPREXIN

TABLET;ORAL

ZEPATIER

| | | | | | | |
|-----|---------------------|------------|---------|-----|--------------|----------|
| >A> | + MERCK SHARP DOHME | 50MG;100MG | N208261 | 001 | Jan 28, 2016 | Jan NEWA |
|-----|---------------------|------------|---------|-----|--------------|----------|

ERGOALCIFEROL

CAPSULE;ORAL

DRISDOL

| | | | | | | |
|--------|----------------------|-----------|---------|-----|--|----------|
| >D> AA | + SANOFI AVENTIS US | 50,000 IU | N003444 | 001 | | Jan CAHN |
| >A> AA | + US PHARM HOLDINGS | 50,000 IU | N003444 | 001 | | Jan CAHN |
| | VITAMIN D | | | | | |
| >D> AA | BANNER LIFE SCIENCES | 50,000 IU | A080704 | 001 | | Jan CAHN |
| >A> AA | BIONPHARMA INC | 50,000 IU | A080704 | 001 | | Jan CAHN |

ERYTHROMYCINSOLUTION;TOPICAL
ERYTHROMYCIN

| | | | | | | | | | |
|-----|----|----------------|------------------|---------|---------|--------------|--------------|------|------|
| >D> | AT | FOUGERA PHARMS | 2% | A064187 | 001 | Sep 30, 1997 | Jan | CRLD | |
| >A> | AT | + | 2% | A064187 | 001 | Sep 30, 1997 | Jan | CRLD | |
| >D> | AT | + | PERRIGO NEW YORK | 2% | A063038 | 001 | Jan 11, 1991 | Jan | CRLD |
| >A> | AT | | 2% | A063038 | 001 | Jan 11, 1991 | Jan | CRLD | |

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINAL
FEMRING

| | | | | | | | | |
|-----|--|----------------------|---------------------|---------|-----|--------------|-----|------|
| >A> | | ALLERGAN PHARMS INTL | EQ 0.05MG BASE/24HR | N021367 | 001 | Mar 20, 2003 | Jan | CAHN |
| >A> | | + | EQ 0.1MG BASE/24HR | N021367 | 002 | Mar 20, 2003 | Jan | CAHN |
| >D> | | WARNER IRELAND | EQ 0.05MG BASE/24HR | N021367 | 001 | Mar 20, 2003 | Jan | CAHN |
| >D> | | + | EQ 0.1MG BASE/24HR | N021367 | 002 | Mar 20, 2003 | Jan | CAHN |

TABLET;ORAL
FEMTRACE

| | | | | | | | | |
|-----|--|----------------------|--------|---------|-----|--------------|-----|------|
| >A> | | ALLERGAN PHARMS INTL | 0.45MG | N021633 | 001 | Aug 20, 2004 | Jan | CAHN |
| >A> | | | 0.9MG | N021633 | 002 | Aug 20, 2004 | Jan | CAHN |
| >A> | | + | 1.8MG | N021633 | 003 | Aug 20, 2004 | Jan | CAHN |
| >D> | | WARNER CHILCOTT LLC | 0.45MG | N021633 | 001 | Aug 20, 2004 | Jan | CAHN |
| >D> | | | 0.9MG | N021633 | 002 | Aug 20, 2004 | Jan | CAHN |
| >D> | | + | 1.8MG | N021633 | 003 | Aug 20, 2004 | Jan | CAHN |

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

| | | | | | | | | |
|-----|----|--|-------------|---------|-----|--------------|-----|------|
| >A> | | ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL | | | | | | |
| >A> | AB | JAI PHARMA LTD | 0.05MG;1MG | A204704 | 001 | Feb 09, 2016 | Jan | NEWA |
| | | ZOVIA 1/50E-28 | | | | | | |
| >D> | | + | WATSON LABS | A072723 | 001 | Dec 30, 1991 | Jan | CTEC |
| >A> | AB | + | 0.05MG;1MG | A072723 | 001 | Dec 30, 1991 | Jan | CTEC |

ETHINYL ESTRADIOL; NORETHINDRONETABLET, CHEWABLE;ORAL
FEMCON FE

| | | | | | | | | | |
|-----|----|---|--|---------------|---------|-----|--------------|-----|------|
| >A> | AB | + | ALLERGAN PHARMS INTL | 0.035MG;0.4MG | N021490 | 001 | Nov 14, 2003 | Jan | CAHN |
| >D> | AB | + | WARNER CHILCOTT LLC | 0.035MG;0.4MG | N021490 | 001 | Nov 14, 2003 | Jan | CAHN |
| | | | NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE | | | | | | |
| >A> | AB | + | ALLERGAN PHARMS INTL | 0.025MG;0.8MG | N022573 | 001 | Dec 22, 2010 | Jan | CAHN |
| >D> | AB | + | WARNER CHILCOTT | 0.025MG;0.8MG | N022573 | 001 | Dec 22, 2010 | Jan | CAHN |

ETHINYL ESTRADIOL; NORETHINDRONE ACETATETABLET;ORAL
FEMHRT

| | | | | | | | | | |
|-----|----|---|----------------------|-----------------------|---------|-----|--------------|-----|------|
| >A> | AB | | ALLERGAN PHARMS INTL | 0.0025MG;0.5MG | N021065 | 001 | Jan 14, 2005 | Jan | CAHN |
| >A> | | @ | | 0.005MG;1MG | N021065 | 002 | Oct 15, 1999 | Jan | CAHN |
| >D> | AB | | WARNER CHILCOTT LLC | 0.0025MG;0.5MG | N021065 | 001 | Jan 14, 2005 | Jan | CAHN |
| >D> | | @ | | 0.005MG;1MG | N021065 | 002 | Oct 15, 1999 | Jan | CAHN |
| | | | LO LOESTRIN FE | | | | | | |
| >A> | | + | ALLERGAN PHARMS INTL | 0.01MG,0.01MG;1MG,N/A | N022501 | 001 | Oct 21, 2010 | Jan | CAHN |
| >D> | | + | WARNER CHILCOTT LLC | 0.01MG,0.01MG;1MG,N/A | N022501 | 001 | Oct 21, 2010 | Jan | CAHN |

TABLET;ORAL-21

ESTROSTEP 21

| | | | | | | | | | |
|-----|--|---|----------------------|-----------------------------------|---------|-----|--------------|-----|------|
| >A> | | @ | ALLERGAN PHARMS INTL | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | N020130 | 001 | Oct 09, 1996 | Jan | CAHN |
| >D> | | @ | WARNER CHILCOTT LLC | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | N020130 | 001 | Oct 09, 1996 | Jan | CAHN |

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

| | | | | | | | | | |
|-----|----|--|---------------------|------------|---------|-----|--------------|-----|------|
| >A> | AB | | GLENMARK PHARMS LTD | 0.02MG;1MG | A206969 | 001 | Jan 20, 2016 | Jan | NEWA |
|-----|----|--|---------------------|------------|---------|-----|--------------|-----|------|

TABLET;ORAL-28

ESTROSTEP FE

| | | | | | | | | | |
|-----|----|---|----------------------|-----------------------------------|---------|-----|--------------|-----|------|
| >A> | AB | + | ALLERGAN PHARMS INTL | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | N020130 | 002 | Oct 09, 1996 | Jan | CAHN |
| >D> | AB | + | WARNER CHILCOTT LLC | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | N020130 | 002 | Oct 09, 1996 | Jan | CAHN |

TABLET, CHEWABLE;ORAL

MINASTRIN 24 FE

| | | | | | | | | | |
|-----|--|---|----------------------|------------|---------|-----|--------------|-----|------|
| >A> | | + | ALLERGAN PHARMS INTL | 0.02MG;1MG | N203667 | 001 | May 08, 2013 | Jan | CAHN |
| >D> | | + | WARNER CHILCOTT LLC | 0.02MG;1MG | N203667 | 001 | May 08, 2013 | Jan | CAHN |

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

| | | | | | | | | | |
|-----|--|---|----------------------|-------------------------------|---------|-----|--------------|-----|------|
| >A> | | + | ALLERGAN PHARMS INTL | 0.01MG,0.01MG,N/A;1MG,N/A,N/A | N204654 | 001 | Jul 24, 2013 | Jan | CAHN |
| >D> | | + | WARNER CHILCOTT | 0.01MG,0.01MG,N/A;1MG,N/A,N/A | N204654 | 001 | Jul 24, 2013 | Jan | CAHN |

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

| | | | | | | | |
|-----|----|----------------|--|---------|-----|--------------|----------|
| >A> | AB | JAI PHARMA LTD | 0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG | A201897 | 001 | Jan 27, 2016 | Jan NEWA |
| >A> | AB | | 0.035MG;0.25MG | A201896 | 001 | Jan 27, 2016 | Jan NEWA |

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

| | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|----------|
| >D> | AB | BANNER LIFE SCIENCES | 250MG | A040430 | 001 | Oct 28, 2002 | Jan CAHN |
| >A> | AB | BIONPHARMA INC | 250MG | A040430 | 001 | Oct 28, 2002 | Jan CAHN |

EXEMESTANE

TABLET;ORAL

EXEMESTANE

| | | | | | | | |
|-----|----|---------------|------|---------|-----|--------------|----------|
| >D> | AB | ALVOGEN INC | 25MG | A200898 | 001 | Jul 28, 2014 | Jan CAHN |
| >A> | AB | ALVOGEN MALTA | 25MG | A200898 | 001 | Jul 28, 2014 | Jan CAHN |

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-12

| | | | | | | | |
|-----|----|-------|------------|---------|-----|--------------|----------|
| >A> | AB | AVEVA | 12.5MCG/HR | A077449 | 005 | Sep 11, 2015 | Jan NEWA |
|-----|----|-------|------------|---------|-----|--------------|----------|

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

| | | | | | | | |
|-----|----|----------------|-----|---------|-----|--------------|----------|
| >D> | AB | ALKEM LABS LTD | 4MG | A204827 | 001 | Dec 10, 2015 | Jan DISC |
| >A> | | @ | 4MG | A204827 | 001 | Dec 10, 2015 | Jan DISC |
| >D> | AB | | 8MG | A204827 | 002 | Dec 10, 2015 | Jan DISC |
| >A> | | @ | 8MG | A204827 | 002 | Dec 10, 2015 | Jan DISC |

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

| | | | | | | | |
|-----|----|-----------------|----------------------|---------|-----|--------------|----------|
| >D> | AP | TEVA PHARMS USA | 200MG/100ML (2MG/ML) | A076653 | 001 | Jul 29, 2004 | Jan DISC |
| >A> | | @ | 200MG/100ML (2MG/ML) | A076653 | 001 | Jul 29, 2004 | Jan DISC |
| >D> | AP | | 400MG/200ML (2MG/ML) | A076653 | 002 | Jul 29, 2004 | Jan DISC |
| >A> | | @ | 400MG/200ML (2MG/ML) | A076653 | 002 | Jul 29, 2004 | Jan DISC |

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

| | | | | | | | |
|-----|--|-------------------|----------------------|---------|-----|--|----------|
| >A> | | @ SPECTRUM PHARMS | 500MG/10ML (50MG/ML) | N012209 | 001 | | Jan CAHN |
| >D> | | @ VALEANT | 500MG/10ML (50MG/ML) | N012209 | 001 | | Jan CAHN |

FLUOXETINE HYDROCHLORIDE

TABLET;ORAL

SARAFEM

| | | | | | | | |
|-----|-----|----------------------|--------------|---------|-----|--------------|----------|
| >A> | AB1 | ALLERGAN PHARMS INTL | EQ 10MG BASE | N021860 | 001 | May 19, 2006 | Jan CAHN |
| >A> | AB1 | | EQ 15MG BASE | N021860 | 002 | May 19, 2006 | Jan CAHN |
| >A> | AB1 | + | EQ 20MG BASE | N021860 | 003 | May 19, 2006 | Jan CAHN |
| >D> | AB1 | WARNER CHILCOTT LLC | EQ 10MG BASE | N021860 | 001 | May 19, 2006 | Jan CAHN |
| >D> | AB1 | | EQ 15MG BASE | N021860 | 002 | May 19, 2006 | Jan CAHN |
| >D> | AB1 | + | EQ 20MG BASE | N021860 | 003 | May 19, 2006 | Jan CAHN |

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

| | | | | | | | |
|-----|----|-----------------|------|---------|-----|--------------|----------|
| >A> | AB | TEVA PHARMS USA | 80MG | A079011 | 001 | Jan 27, 2016 | Jan NEWA |
|-----|----|-----------------|------|---------|-----|--------------|----------|

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

| | | | | | | | |
|-----|----|---------------------|------|---------|-----|--------------|----------|
| >D> | AB | ACTAVIS LABS FL INC | 10MG | A076620 | 001 | Oct 15, 2004 | Jan DISC |
| >A> | | @ | 10MG | A076620 | 001 | Oct 15, 2004 | Jan DISC |
| >D> | AB | | 20MG | A076620 | 002 | Oct 15, 2004 | Jan DISC |
| >A> | | @ | 20MG | A076620 | 002 | Oct 15, 2004 | Jan DISC |
| >D> | AB | | 40MG | A076620 | 003 | Oct 15, 2004 | Jan DISC |
| >A> | | @ | 40MG | A076620 | 003 | Oct 15, 2004 | Jan DISC |

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|-----|----|---------------------|-------------|---------|-----|--------------|-----|------|
| >D> | AB | ACTAVIS LABS FL INC | 10MG;12.5MG | A076608 | 001 | Dec 03, 2004 | Jan | DISC |
| >A> | | @ | 10MG;12.5MG | A076608 | 001 | Dec 03, 2004 | Jan | DISC |
| >D> | AB | | 20MG;12.5MG | A076608 | 002 | Dec 03, 2004 | Jan | DISC |
| >A> | | @ | 20MG;12.5MG | A076608 | 002 | Dec 03, 2004 | Jan | DISC |

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

| | | | | | | | | |
|-----|--|----------------------|---------|---------|-----|--------------|-----|------|
| >A> | | @ EUROHLTH INTL SARL | 10MG/ML | A071439 | 001 | Sep 14, 1990 | Jan | CAHN |
| >D> | | @ HIKMA MAPLE | 10MG/ML | A071439 | 001 | Sep 14, 1990 | Jan | CAHN |

TABLET; ORAL

LASIX

| | | | | | | | | |
|-----|----|-------------------|------|---------|-----|--|-----|------|
| >D> | AB | SANOFI AVENTIS US | 20MG | N016273 | 002 | | Jan | CAHN |
| >D> | AB | | 40MG | N016273 | 001 | | Jan | CAHN |
| >D> | AB | + | 80MG | N016273 | 003 | | Jan | CAHN |
| >A> | AB | US PHARM HOLDINGS | 20MG | N016273 | 002 | | Jan | CAHN |
| >A> | AB | | 40MG | N016273 | 001 | | Jan | CAHN |
| >A> | AB | + | 80MG | N016273 | 003 | | Jan | CAHN |

GABAPENTIN

TABLET; ORAL

GABAPENTIN

| | | | | | | | | |
|-----|----|--------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | SCIEGEN PHARMS INC | 600MG | A205101 | 001 | Feb 04, 2016 | Jan | NEWA |
| >A> | AB | | 800MG | A205101 | 002 | Feb 04, 2016 | Jan | NEWA |

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

| | | | | | | | | |
|-----|----|---------------------|-----|---------|-----|--------------|-----|------|
| >D> | AB | ACTAVIS LABS FL INC | 1MG | A076995 | 001 | Apr 27, 2010 | Jan | DISC |
| >A> | | @ | 1MG | A076995 | 001 | Apr 27, 2010 | Jan | DISC |
| >D> | AB | | 2MG | A076995 | 002 | Apr 27, 2010 | Jan | DISC |
| >A> | | @ | 2MG | A076995 | 002 | Apr 27, 2010 | Jan | DISC |
| >D> | AB | | 4MG | A076995 | 003 | Apr 27, 2010 | Jan | DISC |
| >A> | | @ | 4MG | A076995 | 003 | Apr 27, 2010 | Jan | DISC |

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

| | | | | | | | | |
|-----|----|------------|--------------|---------|-----|--------------|-----|------|
| >D> | AB | COREPHARMA | 1.25MG;250MG | A076731 | 001 | Nov 19, 2004 | Jan | DISC |
| >A> | | @ | 1.25MG;250MG | A076731 | 001 | Nov 19, 2004 | Jan | DISC |
| >D> | AB | | 2.5MG;500MG | A076731 | 002 | Nov 19, 2004 | Jan | DISC |
| >A> | | @ | 2.5MG;500MG | A076731 | 002 | Nov 19, 2004 | Jan | DISC |
| >D> | AB | | 5MG;500MG | A076731 | 003 | Nov 19, 2004 | Jan | DISC |
| >A> | | @ | 5MG;500MG | A076731 | 003 | Nov 19, 2004 | Jan | DISC |

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

| | | | | | | | | |
|-----|----|-------------------|-----|---------|-----|--------------|-----|------|
| >A> | AA | RISING PHARMS INC | 1MG | A040821 | 001 | Dec 29, 2008 | Jan | CAHN |
| >A> | AA | | 2MG | A040821 | 002 | Dec 29, 2008 | Jan | CAHN |
| >D> | AA | VINTAGE | 1MG | A040821 | 001 | Dec 29, 2008 | Jan | CAHN |
| >D> | AA | | 2MG | A040821 | 002 | Dec 29, 2008 | Jan | CAHN |
| | | ROBINUL | | | | | | |
| >A> | AA | + CASPER PHARMA | 1MG | N012827 | 001 | | Jan | CAHN |
| >D> | AA | + SHIONOGI INC | 1MG | N012827 | 001 | | Jan | CAHN |
| | | ROBINUL FORTE | | | | | | |
| >A> | AA | + CASPER PHARMA | 2MG | N012827 | 002 | | Jan | CAHN |
| >D> | AA | + SHIONOGI INC | 2MG | N012827 | 002 | | Jan | CAHN |

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

| | | | | | | | | |
|-----|----|----------------------|----------------------------------|---------|-----|--------------|-----|------|
| >D> | AP | BANNER LIFE SCIENCES | EQ 0.1MG BASE/ML (EQ 0.1MG | A078863 | 001 | Jun 30, 2008 | Jan | CAHN |
| | | | BASE/ML) | | | | | |
| >D> | AP | | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A078880 | 001 | Jun 30, 2008 | Jan | CAHN |
| >A> | AP | BIONPHARMA INC | EQ 0.1MG BASE/ML (EQ 0.1MG | A078863 | 001 | Jun 30, 2008 | Jan | CAHN |
| | | | BASE/ML) | | | | | |
| >A> | AP | | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A078880 | 001 | Jun 30, 2008 | Jan | CAHN |
| >A> | AP | HIKMA FARMACEUTICA | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A078629 | 001 | Dec 23, 2009 | Jan | CMS1 |

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

| | | | | | | | |
|-----|----|----------------------|---|----------|-----|--------------|----------|
| >A> | AP | | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A 078629 | 002 | Dec 23, 2009 | Jan CMS1 |
| | | | GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| >D> | AP | BANNER LIFE SCIENCES | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A 078863 | 002 | Jun 30, 2008 | Jan CAHN |
| >A> | AP | BIONPHARMA INC | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A 078863 | 002 | Jun 30, 2008 | Jan CAHN |
| | | | GRANISTERON HYDROCHLORIDE | | | | |
| >D> | AP | HIKMA FARMACEUTICA | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A 078629 | 001 | Dec 23, 2009 | Jan CMS1 |
| >D> | AP | | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A 078629 | 002 | Dec 23, 2009 | Jan CMS1 |

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

| | | | | | | | |
|-----|--|-----------|-------|----------|-----|--------------|----------|
| >D> | | @ ROXANE | 2MG | A 071130 | 001 | Feb 17, 1987 | Jan CAHN |
| >A> | | @ | 2MG | A 071130 | 001 | Feb 17, 1987 | Jan CAHN |
| >A> | | @ VINTAGE | 0.5MG | A 071235 | 002 | Nov 03, 1986 | Jan CMS1 |
| >A> | | @ | 1MG | A 071235 | 003 | Nov 03, 1986 | Jan CMS1 |
| >A> | | @ | 5MG | A 071235 | 004 | Nov 03, 1986 | Jan CMS1 |
| >A> | | @ | 10MG | A 071235 | 005 | Jul 20, 1987 | Jan CMS1 |

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

| | | | | | | | |
|-----|--|---------------------|--|----------|-----|--------------|----------|
| >A> | | @ ACTAVIS ELIZABETH | 1.5MG; 5MG | A 040295 | 001 | Dec 01, 2000 | Jan CMS1 |
| | | | HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE | | | | |
| >D> | | @ ACTAVIS ELIZABETH | 1.5MG; 5MG | A 040295 | 001 | Dec 01, 2000 | Jan CMS1 |

HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETIC

| | | | | | | | |
|-----|----|--------|------|----------|-----|--|----------|
| >D> | AB | ABBVIE | 50MG | N 011971 | 002 | | Jan DISC |
| >A> | | @ | 50MG | N 011971 | 002 | | Jan DISC |

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|-----|----|-------------------|---------------|----------|-----|--------------|----------|
| >A> | AB | INTL SPECLT CHEMS | 12.5MG; 150MG | A 203036 | 001 | Jan 15, 2016 | Jan NEWA |
| >A> | AB | | 12.5MG; 300MG | A 203036 | 002 | Jan 15, 2016 | Jan NEWA |
| >A> | | | 25MG; 300MG | A 203036 | 003 | Jan 15, 2016 | Jan NEWA |

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

ZESTORETIC

| | | | | | | | |
|-----|----|-------------------|--------------|----------|-----|--------------|----------|
| >D> | AB | ALVOGEN IPCO SARL | 12.5MG; 10MG | N 019888 | 003 | Nov 18, 1993 | Jan CAHN |
| >D> | AB | + | 12.5MG; 20MG | N 019888 | 001 | Sep 20, 1990 | Jan CAHN |
| >D> | AB | + | 25MG; 20MG | N 019888 | 002 | Jul 20, 1989 | Jan CAHN |
| >A> | AB | ALVOGEN MALTA | 12.5MG; 10MG | N 019888 | 003 | Nov 18, 1993 | Jan CAHN |
| >A> | AB | + | 12.5MG; 20MG | N 019888 | 001 | Sep 20, 1990 | Jan CAHN |
| >A> | AB | + | 25MG; 20MG | N 019888 | 002 | Jul 20, 1989 | Jan CAHN |

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|-----|----|--------------|---------------|----------|-----|--------------|----------|
| >A> | AB | PRINSTON INC | 12.5MG; 80MG | A 206083 | 001 | Feb 08, 2016 | Jan NEWA |
| >A> | AB | | 12.5MG; 160MG | A 206083 | 002 | Feb 08, 2016 | Jan NEWA |
| >A> | AB | | 12.5MG; 320MG | A 206083 | 003 | Feb 08, 2016 | Jan NEWA |
| >A> | AB | | 25MG; 160MG | A 206083 | 004 | Feb 08, 2016 | Jan NEWA |
| >A> | AB | | 25MG; 320MG | A 206083 | 005 | Feb 08, 2016 | Jan NEWA |

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

| | | | | | | | |
|-----|----|---------------------|------------|----------|-----|--------------|----------|
| >D> | AB | ACTAVIS LABS FL INC | 5MG; 200MG | A 077454 | 001 | Jun 23, 2010 | Jan DISC |
| >A> | | @ | 5MG; 200MG | A 077454 | 001 | Jun 23, 2010 | Jan DISC |

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

PEDIOTIC

| | | | | | | | |
|-----|----|----------------|---------------------------------------|----------|-----|--------------|----------|
| >D> | AT | MONARCH PHARMS | 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML | A 062822 | 001 | Sep 29, 1987 | Jan DISC |
| >A> | | @ | 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML | A 062822 | 001 | Sep 29, 1987 | Jan DISC |

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT

| | | | | | | | |
|-----|------------|----------------------|---------|-----|--------------|-----|------|
| >A> | @ SERB SA | 2.5GM/VIAL (5GM/KIT) | N022041 | 002 | Dec 15, 2006 | Jan | CAHN |
| >A> | + | 5GM/VIAL (5GM/KIT) | N022041 | 001 | Apr 08, 2011 | Jan | CAHN |
| >D> | @ SERB SAS | 2.5GM/VIAL (5GM/KIT) | N022041 | 002 | Dec 15, 2006 | Jan | CAHN |
| >D> | + | 5GM/VIAL (5GM/KIT) | N022041 | 001 | Apr 08, 2011 | Jan | CAHN |

HYDROXYPROGESTERONE CAPROATEINJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

| | | | | | | | | |
|-----|---|------------------|----------|---------|-----|--------------|-----|------|
| >A> | + | ASPEN GLOBAL INC | 250MG/ML | A200271 | 001 | Aug 24, 2015 | Jan | CAHN |
| >D> | + | MCGUFF | 250MG/ML | A200271 | 001 | Aug 24, 2015 | Jan | CAHN |

IBANDRONATE SODIUMINJECTABLE; INTRAVENOUS
IBANDRONATE SODIUM

| | | | | | | | | |
|-----|----|-----------------|-----------------|---------|-----|--------------|-----|------|
| >A> | AP | ACCORD HLTHCARE | EQ 3MG BASE/3ML | A206058 | 001 | Feb 05, 2016 | Jan | NEWA |
|-----|----|-----------------|-----------------|---------|-----|--------------|-----|------|

INDIUM IN-111 CHLORIDEINJECTABLE; INJECTION
INDIUM IN 111 CHLORIDE

| | | | | | | | | |
|-----|---|---------------------|------------|---------|-----|--------------|-----|------|
| >D> | + | MALLINCKRODT | 5mCi/0.5ML | N019841 | 001 | Sep 27, 1994 | Jan | CAHN |
| >A> | + | MALLINKRODT NUCLEAR | 5mCi/0.5ML | N019841 | 001 | Sep 27, 1994 | Jan | CAHN |

INDIUM IN-111 PENTETREOTIDE KITINJECTABLE; INJECTION
OCTREOSCAN

| | | | | | | | | |
|-----|---|---------------------|---------|---------|-----|--------------|-----|------|
| >D> | + | MALLINCKRODT | 3mCi/ML | N020314 | 001 | Jun 02, 1994 | Jan | CAHN |
| >A> | + | MALLINKRODT NUCLEAR | 3mCi/ML | N020314 | 001 | Jun 02, 1994 | Jan | CAHN |

INDOCYANINE GREENINJECTABLE; INJECTION
INDOCYANINE GREEN

| | | | | | | | | |
|-----|----|------------------|-----------|---------|-----|--------------|-----|------|
| >A> | AP | DIAGNOSTIC GREEN | 25MG/VIAL | A040811 | 001 | Nov 21, 2007 | Jan | CAHN |
| >D> | AP | PULSION MEDCL | 25MG/VIAL | A040811 | 001 | Nov 21, 2007 | Jan | CAHN |

>A> INSULIN HUMANSOLUTION; SUBCUTANEOUS
HUMULIN R

| | | | | | | | | |
|-----|---|-------------------|---------------------------------|---------|-----|--------------|-----|------|
| >A> | + | LILLY | 10000 UNITS/20ML (500 UNITS/ML) | N018780 | 004 | Mar 31, 1994 | Jan | CAIN |
| >A> | | HUMULIN R KWIKPEN | | | | | | |
| >A> | + | LILLY | 1500 UNITS/3ML (500 UNITS/ML) | N018780 | 002 | Dec 29, 2015 | Jan | NEWA |

>D> INSULIN RECOMBINANT HUMANINJECTABLE; INJECTION
HUMULIN R

| | | | | | | | | |
|-----|---|-------|--------------|---------|-----|--------------|-----|------|
| >D> | + | LILLY | 500 UNITS/ML | N018780 | 004 | Mar 31, 1994 | Jan | CAIN |
|-----|---|-------|--------------|---------|-----|--------------|-----|------|

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------------|---------------------|---------|-----|--------------|-----|------|
| >D> | AP | EBEWE PHARMA | 40MG/2ML (20MG/ML) | A090137 | 001 | Nov 12, 2009 | Jan | CAHN |
| >D> | AP | | 100MG/5ML (20MG/ML) | A090137 | 002 | Nov 12, 2009 | Jan | CAHN |
| >A> | AP | SANDOZ INC | 40MG/2ML (20MG/ML) | A090137 | 001 | Nov 12, 2009 | Jan | CAHN |
| >A> | AP | | 100MG/5ML (20MG/ML) | A090137 | 002 | Nov 12, 2009 | Jan | CAHN |

ISOSULFAN BLUEINJECTABLE; INJECTION
ISOSULFAN BLUE

| | | | | | | | | |
|-----|----|----------------------|----|---------|-----|--------------|-----|------|
| >A> | AP | AUROBINDO PHARMA LTD | 1% | A206831 | 001 | Feb 02, 2016 | Jan | NEWA |
| >D> | + | MYLAN INSTITUTIONAL | 1% | A090874 | 001 | Jul 20, 2010 | Jan | CTEC |
| >A> | AP | + | 1% | A090874 | 001 | Jul 20, 2010 | Jan | CTEC |

KETOCONAZOLETABLET; ORAL
KETOCONAZOLE

| | | | | | | | | |
|-----|---|----------------|-------|---------|-----|--------------|-----|------|
| >D> | @ | MUTUAL PHARMA | 200MG | A075314 | 001 | Jun 15, 1999 | Jan | CAHN |
| >A> | @ | SUN PHARM INDS | 200MG | A075314 | 001 | Jun 15, 1999 | Jan | CAHN |

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

| | | | | | | | | | |
|-----|----|-------------------------|--------|---------|-----|--------------|-----|------|--|
| >A> | | LABETALOL HYDROCHLORIDE | | | | | | | |
| >A> | AP | SAGENT STRIDES | 5MG/ML | A079134 | 001 | Feb 03, 2010 | Jan | CTNA | |
| >D> | | LABETALOL HYDROCHLORIDE | | | | | | | |
| >D> | AP | SAGENT STRIDES | 5MG/ML | A079134 | 001 | Feb 03, 2010 | Jan | CTNA | |
| | | TRANDATE | | | | | | | |
| >D> | | @ PROMETHEUS LABS | 5MG/ML | N019425 | 001 | Dec 31, 1985 | Jan | CAHN | |
| >A> | | @ SEBELA IRELAND LTD | 5MG/ML | N019425 | 001 | Dec 31, 1985 | Jan | CAHN | |
| | | TABLET; ORAL | | | | | | | |
| | | LABETALOL HYDROCHLORIDE | | | | | | | |
| >D> | AB | MUTUAL PHARM | 100MG | A075215 | 001 | Jul 29, 1999 | Jan | CAHN | |
| >D> | AB | | 200MG | A075215 | 002 | Jul 29, 1999 | Jan | CAHN | |
| >D> | AB | | 300MG | A075215 | 003 | Jul 29, 1999 | Jan | CAHN | |
| >A> | AB | NOSTRUM LABS INC | 100MG | A075215 | 001 | Jul 29, 1999 | Jan | CAHN | |
| >A> | AB | | 200MG | A075215 | 002 | Jul 29, 1999 | Jan | CAHN | |
| >A> | AB | | 300MG | A075215 | 003 | Jul 29, 1999 | Jan | CAHN | |

LAMOTRIGINE

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

| | | | | | | | | | |
|-----|----|---------------------|-------|---------|-----|--------------|-----|------|--|
| >D> | AB | GLAXOSMITHKLINE LLC | 200MG | N022115 | 004 | May 29, 2009 | Jan | CRLD | |
| >A> | AB | + | 200MG | N022115 | 004 | May 29, 2009 | Jan | CRLD | |

LETROZOLE

TABLET; ORAL

LETROZOLE

| | | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|--|
| >A> | AB | KREMERS URBAN PHARMS | 2.5MG | A091098 | 001 | Jun 03, 2011 | Jan | CAHN | |
| >D> | AB | KUDCO IRELAND | 2.5MG | A091098 | 001 | Jun 03, 2011 | Jan | CAHN | |

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

| | | | | | | | | | |
|-----|----|----------------------|----------------------|---------|-----|--------------|-----|------|--|
| >A> | AP | AUROBINDO PHARMA LTD | 500MG/5ML (100MG/ML) | A204312 | 001 | Feb 01, 2016 | Jan | NEWA | |
|-----|----|----------------------|----------------------|---------|-----|--------------|-----|------|--|

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | | | |
|-----|----|----------------------|----------------------------|---------|-----|--------------|-----|------|--|
| >A> | AP | AUROBINDO PHARMA LTD | EQ 250MG/50ML (EQ 5MG/ML) | A206919 | 001 | Feb 10, 2016 | Jan | NEWA | |
| >A> | AP | | EQ 500MG/100ML (EQ 5MG/ML) | A206919 | 002 | Feb 10, 2016 | Jan | NEWA | |
| >A> | AP | | EQ 750MG/150ML (EQ 5MG/ML) | A206919 | 003 | Feb 10, 2016 | Jan | NEWA | |

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

| | | | | | | | | | |
|-----|----|---|-------------------|------|---------|-----|--------------|-----|------|
| >D> | AT | + | NEXUS PHARMS | 0.5% | A077700 | 001 | Dec 20, 2010 | Jan | CAHN |
| >A> | AT | + | RISING PHARMS INC | 0.5% | A077700 | 001 | Dec 20, 2010 | Jan | CAHN |

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

| | | | | | | | | | |
|-----|----|---------------------|----|---------|-----|--------------|-----|------|--|
| >A> | AT | TELIGENT PHARMA INC | 5% | A205318 | 001 | Feb 01, 2016 | Jan | NEWA | |
|-----|----|---------------------|----|---------|-----|--------------|-----|------|--|

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

ANESTACON

| | | | | | | | | | |
|-----|--|------------------------|----|---------|-----|--|-----|------|--|
| >D> | | @ BANNER LIFE SCIENCES | 2% | A080429 | 001 | | Jan | CAHN | |
| >A> | | @ BIONPHARMA INC | 2% | A080429 | 001 | | Jan | CAHN | |

LINEZOLID

TABLET; ORAL

LINEZOLID

| | | | | | | | | | |
|-----|----|-------------|-------|---------|-----|--------------|-----|------|--|
| >A> | AB | GATE PHARMS | 600MG | A091210 | 001 | Feb 05, 2016 | Jan | NEWA | |
|-----|----|-------------|-------|---------|-----|--------------|-----|------|--|

LISINAPRIL

TABLET; ORAL

ZESTRIL

| | | | | | | | | | |
|-----|----|-------------------|-------|---------|-----|--------------|-----|------|--|
| >D> | AB | ALVOGEN IPCO SARL | 2.5MG | N019777 | 005 | Apr 29, 1993 | Jan | CAHN | |
| >D> | AB | | 5MG | N019777 | 001 | May 19, 1988 | Jan | CAHN | |
| >D> | AB | | 10MG | N019777 | 002 | May 19, 1988 | Jan | CAHN | |
| >D> | AB | | 20MG | N019777 | 003 | May 19, 1988 | Jan | CAHN | |
| >D> | AB | | 30MG | N019777 | 006 | Jan 20, 1999 | Jan | CAHN | |
| >D> | AB | + | 40MG | N019777 | 004 | May 19, 1988 | Jan | CAHN | |

TABLET;ORAL

ZESTRIL

| | | | | | | | |
|-----|----|---------------|-------|---------|-----|--------------|----------|
| >A> | AB | ALVOGEN MALTA | 2.5MG | N019777 | 005 | Apr 29, 1993 | Jan CAHN |
| >A> | AB | | 5MG | N019777 | 001 | May 19, 1988 | Jan CAHN |
| >A> | AB | | 10MG | N019777 | 002 | May 19, 1988 | Jan CAHN |
| >A> | AB | | 20MG | N019777 | 003 | May 19, 1988 | Jan CAHN |
| >A> | AB | | 30MG | N019777 | 006 | Jan 20, 1999 | Jan CAHN |
| >A> | AB | + | 40MG | N019777 | 004 | May 19, 1988 | Jan CAHN |

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

| | | | | | | | |
|-----|----|--------------------|-------|---------|-----|--------------|----------|
| >A> | AB | HIKMA PHARMS | 600MG | A078763 | 001 | Apr 15, 2008 | Jan CMFD |
| >D> | | @ HIKMA PHARMS LLC | 600MG | A078763 | 001 | Apr 15, 2008 | Jan CMFD |

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

| | | | | | | | |
|-----|---|----------|--------------|---------|-----|--------------|----------|
| >D> | + | AEGERION | EQ 20MG BASE | N203858 | 003 | Dec 21, 2012 | Jan CRLD |
| >A> | | | EQ 20MG BASE | N203858 | 003 | Dec 21, 2012 | Jan CRLD |
| >D> | | | EQ 60MG BASE | N203858 | 006 | Apr 23, 2015 | Jan CRLD |
| >A> | + | | EQ 60MG BASE | N203858 | 006 | Apr 23, 2015 | Jan CRLD |

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

| | | | | | | | |
|-----|---|--------------------|----------------------|---------|-----|--------------|----------|
| >A> | + | FRESENIUS KABI USA | 10GM/20ML (500MG/ML) | N019316 | 003 | Jan 29, 2016 | Jan NEWA |
| >A> | + | | 25GM/50ML (500MG/ML) | N019316 | 004 | Jan 29, 2016 | Jan NEWA |

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

| | | | | | | | |
|-----|--|---------------------|--------|---------|-----|--------------|----------|
| >A> | | @ RISING PHARMS INC | 12.5MG | A040179 | 001 | Jan 30, 1997 | Jan CAHN |
| >A> | | @ | 25MG | A040179 | 002 | Jan 30, 1997 | Jan CAHN |
| >D> | | @ VINTAGE PHARMS | 12.5MG | A040179 | 001 | Jan 30, 1997 | Jan CAHN |
| >D> | | @ | 25MG | A040179 | 002 | Jan 30, 1997 | Jan CAHN |

MELOXICAM

TABLET;ORAL

MELOXICAM

| | | | | | | | |
|-----|--|------------------|-------|---------|-----|--------------|----------|
| >D> | | @ MUTUAL PHARM | 7.5MG | A077935 | 001 | Jul 19, 2006 | Jan CAHN |
| >D> | | @ | 15MG | A077935 | 002 | Jul 19, 2006 | Jan CAHN |
| >A> | | @ SUN PHARM INDS | 7.5MG | A077935 | 001 | Jul 19, 2006 | Jan CAHN |
| >A> | | @ | 15MG | A077935 | 002 | Jul 19, 2006 | Jan CAHN |

MELPHALAN

TABLET;ORAL

ALKERAN

| | | | | | | | |
|-----|---|-----------------|-----|---------|-----|--|----------|
| >A> | + | APOTEX INC | 2MG | N014691 | 002 | | Jan CAHN |
| >D> | + | GLAXOSMITHKLINE | 2MG | N014691 | 002 | | Jan CAHN |

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

| | | | | | | | | |
|-----|----|---|-----------------|-------------------|---------|-----|--------------|----------|
| >A> | AP | + | APOTEX INC | EQ 50MG BASE/VIAL | N020207 | 001 | Nov 18, 1992 | Jan CAHN |
| >D> | AP | + | GLAXOSMITHKLINE | EQ 50MG BASE/VIAL | N020207 | 001 | Nov 18, 1992 | Jan CAHN |

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

| | | | | | | | |
|-----|--|---------------------|----------|---------|-----|--|----------|
| >D> | | @ SANOFI AVENTIS US | 25MG/ML | N005010 | 007 | | Jan CAHN |
| >D> | | @ | 50MG/ML | N005010 | 002 | | Jan CAHN |
| >D> | | @ | 75MG/ML | N005010 | 009 | | Jan CAHN |
| >D> | | @ | 100MG/ML | N005010 | 003 | | Jan CAHN |
| >A> | | @ US PHARM HOLDINGS | 25MG/ML | N005010 | 007 | | Jan CAHN |
| >A> | | @ | 50MG/ML | N005010 | 002 | | Jan CAHN |
| >A> | | @ | 75MG/ML | N005010 | 009 | | Jan CAHN |
| >A> | | @ | 100MG/ML | N005010 | 003 | | Jan CAHN |

SYRUP;ORAL

DEMEROL

| | | | | | | | |
|-----|--|---------------------|----------|---------|-----|--|----------|
| >D> | | @ SANOFI AVENTIS US | 50MG/5ML | N005010 | 005 | | Jan CAHN |
| >A> | | @ US PHARM HOLDINGS | 50MG/5ML | N005010 | 005 | | Jan CAHN |

TABLET;ORAL
DEMEROL

| | | | | | | | | | |
|-----|----|---|-------------------|-------|---------|-----|--|-----|------|
| >D> | AA | + | SANOFI AVENTIS US | 50MG | N005010 | 001 | | Jan | CAHN |
| >D> | AA | + | | 100MG | N005010 | 004 | | Jan | CAHN |
| >A> | AA | + | US PHARM HOLDINGS | 50MG | N005010 | 001 | | Jan | CAHN |
| >A> | AA | + | | 100MG | N005010 | 004 | | Jan | CAHN |

MERCAPTOPURINE

TABLET;ORAL
PURINETHOL

| | | | | | | | | | |
|-----|--|---|---------------|------|---------|-----|--|-----|------|
| >A> | | @ | STASON PHARMS | 50MG | N009053 | 002 | | Jan | CAHN |
| >D> | | @ | TEVA | 50MG | N009053 | 002 | | Jan | CAHN |

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL
DELZICOL

| | | | | | | | | | |
|-----|--|---|----------------------|-------|---------|-----|--------------|-----|------|
| >A> | | + | ALLERGAN PHARMS INTL | 400MG | N204412 | 001 | Feb 01, 2013 | Jan | CAHN |
| >D> | | + | WARNER CHILCOTT LLC | 400MG | N204412 | 001 | Feb 01, 2013 | Jan | CAHN |

TABLET, DELAYED RELEASE;ORAL
ASACOL

| | | | | | | | | | |
|-----|--|---|----------------------|-------|---------|-----|--------------|-----|------|
| >A> | | @ | ALLERGAN PHARMS INTL | 400MG | N019651 | 001 | Jan 31, 1992 | Jan | CAHN |
| >D> | | @ | WARNER CHILCOTT LLC | 400MG | N019651 | 001 | Jan 31, 1992 | Jan | CAHN |
| >A> | | + | ALLERGAN PHARMS INTL | 800MG | N021830 | 001 | May 29, 2008 | Jan | CAHN |
| >D> | | + | WARNER CHILCOTT LLC | 800MG | N021830 | 001 | May 29, 2008 | Jan | CAHN |

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GLUMETZA

| | | | | | | | | | |
|-----|-----|---|--------------|-------|---------|-----|--------------|-----|------|
| >D> | | | SANTARUS INC | 500MG | N021748 | 001 | Jun 03, 2005 | Jan | CTEC |
| >A> | AB3 | | | 500MG | N021748 | 001 | Jun 03, 2005 | Jan | CTEC |
| >D> | | + | | 1GM | N021748 | 002 | Jun 03, 2005 | Jan | CTEC |
| >A> | AB3 | + | | 1GM | N021748 | 002 | Jun 03, 2005 | Jan | CTEC |

METHENAMINE HIPPURATE

TABLET;ORAL
HIPREX

| | | | | | | | | | |
|-----|----|---|-------------------|-----|---------|-----|--|-----|------|
| >D> | AB | + | SANOFI AVENTIS US | 1GM | N017681 | 001 | | Jan | CAHN |
| >A> | AB | + | US PHARM HOLDINGS | 1GM | N017681 | 001 | | Jan | CAHN |

METHIMAZOLE

TABLET;ORAL
METHIMAZOLE

| | | | | | | | | | |
|-----|----|--|-------------------|------|---------|-----|--------------|-----|------|
| >A> | AB | | RISING PHARMS INC | 5MG | A202068 | 001 | Mar 07, 2012 | Jan | CAHN |
| >A> | AB | | | 10MG | A202068 | 002 | Mar 07, 2012 | Jan | CAHN |
| >D> | AB | | VINTAGE PHARMS | 5MG | A202068 | 001 | Mar 07, 2012 | Jan | CAHN |
| >D> | AB | | | 10MG | A202068 | 002 | Mar 07, 2012 | Jan | CAHN |

METHOTREXATE SODIUM

INJECTABLE;INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE

| | | | | | | | | | |
|-----|----|--|--------------|--------------------------------------|---------|-----|--------------|-----|------|
| >D> | AP | | EBEWE PHARMA | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A090039 | 001 | Mar 31, 2009 | Jan | CAHN |
| >D> | AP | | | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A090039 | 002 | Mar 31, 2009 | Jan | CAHN |
| >D> | AP | | | EQ 1GM BASE/40ML (EQ 25MG BASE/ML) | A090029 | 001 | Mar 31, 2009 | Jan | CAHN |
| >A> | AP | | SANDOZ INC | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A090039 | 001 | Mar 31, 2009 | Jan | CAHN |
| >A> | AP | | | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A090039 | 002 | Mar 31, 2009 | Jan | CAHN |
| >A> | AP | | | EQ 1GM BASE/40ML (EQ 25MG BASE/ML) | A090029 | 001 | Mar 31, 2009 | Jan | CAHN |

METHYLERGONOVINE MALEATE

TABLET;ORAL
METHERGINE

| | | | | | | | | | |
|-----|----|---|--------------------|-------|---------|-----|--------------|-----|------|
| >D> | | | EDISON THERAPS LLC | 0.2MG | N006035 | 003 | | Jan | DISC |
| >A> | | @ | | 0.2MG | N006035 | 003 | | Jan | DISC |
| >D> | AB | | NOVEL LABS INC | 0.2MG | A091577 | 001 | May 02, 2011 | Jan | CRLD |
| >A> | | + | | 0.2MG | A091577 | 001 | May 02, 2011 | Jan | CRLD |

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

| | | | | | | | |
|-----|----|----------------|--------------------|---------|-----|--------------|----------|
| >D> | AP | MUSTAFA NEVSAT | EQ 40MG BASE/VIAL | A040888 | 001 | Jul 18, 2011 | Jan CAHN |
| >D> | AP | | EQ 125MG BASE/VIAL | A040888 | 002 | Jul 18, 2011 | Jan CAHN |
| >D> | AP | | EQ 500MG BASE/VIAL | A040888 | 003 | Jul 18, 2011 | Jan CAHN |
| >D> | AP | | EQ 1GM BASE/VIAL | A040888 | 004 | Jul 18, 2011 | Jan CAHN |
| >D> | AP | | EQ 2GM BASE/VIAL | A040888 | 005 | Jul 18, 2011 | Jan CAHN |
| >A> | AP | SAGENT PHARMS | EQ 40MG BASE/VIAL | A040888 | 001 | Jul 18, 2011 | Jan CAHN |
| >A> | AP | | EQ 125MG BASE/VIAL | A040888 | 002 | Jul 18, 2011 | Jan CAHN |
| >A> | AP | | EQ 500MG BASE/VIAL | A040888 | 003 | Jul 18, 2011 | Jan CAHN |
| >A> | AP | | EQ 1GM BASE/VIAL | A040888 | 004 | Jul 18, 2011 | Jan CAHN |
| >A> | AP | | EQ 2GM BASE/VIAL | A040888 | 005 | Jul 18, 2011 | Jan CAHN |

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

| | | | | | | | |
|-----|----|------------------|-------|---------|-----|--------------|----------|
| >D> | AB | MUTUAL PHARM | 250MG | A070772 | 001 | Jul 16, 1986 | Jan CAHN |
| >D> | AB | | 500MG | A070773 | 001 | Jul 16, 1986 | Jan CAHN |
| >A> | AB | NOSTRUM LABS INC | 250MG | A070772 | 001 | Jul 16, 1986 | Jan CAHN |
| >A> | AB | | 500MG | A070773 | 001 | Jul 16, 1986 | Jan CAHN |

MICONAZOLE

TABLET; BUCCAL

ORAVIG

| | | | | | | | |
|-----|---|--------------------|------|---------|-----|--------------|----------|
| >D> | + | DARA BIOSCIENCES | 50MG | N022404 | 001 | Apr 16, 2010 | Jan CAHN |
| >A> | + | MIDATECH PHARMA US | 50MG | N022404 | 001 | Apr 16, 2010 | Jan CAHN |

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

| | | | | | | | |
|-----|---|--------------------|--------|---------|-----|--------------|----------|
| >A> | @ | LIBERTY PHARMA INC | 12.5MG | A205071 | 001 | Jan 27, 2016 | Jan DISC |
| >A> | | | 12.5MG | A205071 | 001 | Jan 27, 2016 | Jan NEWA |
| >A> | @ | | 25MG | A205071 | 002 | Jan 27, 2016 | Jan DISC |
| >A> | | | 25MG | A205071 | 002 | Jan 27, 2016 | Jan NEWA |
| >A> | @ | | 50MG | A205071 | 003 | Jan 27, 2016 | Jan DISC |
| >A> | | | 50MG | A205071 | 003 | Jan 27, 2016 | Jan NEWA |
| >A> | @ | | 100MG | A205071 | 004 | Jan 27, 2016 | Jan DISC |
| >A> | | | 100MG | A205071 | 004 | Jan 27, 2016 | Jan NEWA |

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

| | | | | | | | |
|-----|----|----------------|---------------|---------|-----|--------------|----------|
| >A> | AB | SUN PHARM INDS | EQ 50MG BASE | A090217 | 001 | Jan 29, 2016 | Jan NEWA |
| >A> | AB | | EQ 75MG BASE | A090217 | 002 | Jan 29, 2016 | Jan NEWA |
| >A> | AB | | EQ 100MG BASE | A090217 | 003 | Jan 29, 2016 | Jan NEWA |

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

| | | | | | | | |
|-----|----|---------------------|------|---------|-----|--------------|----------|
| >D> | AB | ACTAVIS LABS FL INC | 15MG | A076336 | 001 | Jun 20, 2003 | Jan DISC |
| >A> | @ | | 15MG | A076336 | 001 | Jun 20, 2003 | Jan DISC |
| >D> | AB | | 30MG | A076336 | 002 | Jun 20, 2003 | Jan DISC |
| >A> | @ | | 30MG | A076336 | 002 | Jun 20, 2003 | Jan DISC |
| >D> | AB | | 45MG | A076336 | 003 | Jun 20, 2003 | Jan DISC |
| >A> | @ | | 45MG | A076336 | 003 | Jun 20, 2003 | Jan DISC |

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

| | | | | | | | |
|-----|----|--------------------|-----------|---------|-----|--------------|----------|
| >A> | AP | EUROHLTH INTL SARL | 5MG/VIAL | A064180 | 001 | Dec 23, 1999 | Jan CAHN |
| >A> | AP | | 20MG/VIAL | A064180 | 002 | Dec 23, 1999 | Jan CAHN |
| >D> | AP | HIKMA MAPLE | 5MG/VIAL | A064180 | 001 | Dec 23, 1999 | Jan CAHN |
| >D> | AP | | 20MG/VIAL | A064180 | 002 | Dec 23, 1999 | Jan CAHN |

MODAFINIL

TABLET; ORAL

MODAFINIL

| | | | | | | | |
|-----|----|-----------------|-------|---------|-----|--------------|----------|
| >D> | AB | CARLSBAD | 100MG | A076715 | 001 | Nov 01, 2012 | Jan CAHN |
| >D> | AB | | 200MG | A076715 | 002 | Nov 01, 2012 | Jan CAHN |
| >A> | AB | WATSON LABS INC | 100MG | A076715 | 001 | Nov 01, 2012 | Jan CAHN |

| | | | | | | | | | |
|---|-----|--|-------------------|---------|-----|--------------|-----|------|--|
| | | TABLET;ORAL | | | | | | | |
| | | MODAFINIL | | | | | | | |
| >A> | AB | 200MG | | A076715 | 002 | Nov 01, 2012 | Jan | CAHN | |
| <u>MOXIFLOXACIN HYDROCHLORIDE</u> | | | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | MOXIFLOXACIN HYDROCHLORIDE | | | | | | | |
| >A> | AB | CROSSMEDIKA SA | EQ 400MG BASE | A205348 | 001 | Jan 14, 2016 | Jan | NEWA | |
| <u>NIFEDIPINE</u> | | | | | | | | | |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| | | NIFEDIPINE | | | | | | | |
| >D> | AB1 | VALEANT INTL | 30MG | A075269 | 001 | Dec 04, 2000 | Jan | CAHN | |
| >D> | AB1 | | 60MG | A075269 | 002 | Dec 04, 2000 | Jan | CAHN | |
| >D> | AB1 | | 90MG | A076070 | 001 | Aug 16, 2002 | Jan | CAHN | |
| >A> | AB1 | VALEANT PHARMS NORTH | 30MG | A075269 | 001 | Dec 04, 2000 | Jan | CAHN | |
| >A> | AB1 | | 60MG | A075269 | 002 | Dec 04, 2000 | Jan | CAHN | |
| >A> | AB1 | | 90MG | A076070 | 001 | Aug 16, 2002 | Jan | CAHN | |
| <u>NIMODIPINE</u> | | | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | NIMODIPINE | | | | | | | |
| >D> | AB | + BANNER LIFE SCIENCES | 30MG | A076740 | 001 | Jan 17, 2008 | Jan | CAHN | |
| >A> | AB | + BIONPHARMA INC | 30MG | A076740 | 001 | Jan 17, 2008 | Jan | CAHN | |
| <u>NITRIC OXIDE</u> | | | | | | | | | |
| | | GAS;INHALATION | | | | | | | |
| | | INOMAX | | | | | | | |
| >D> | | @ INO | 100PPM | N020845 | 002 | Dec 23, 1999 | Jan | CAHN | |
| >D> | | + | 800PPM | N020845 | 003 | Dec 23, 1999 | Jan | CAHN | |
| >A> | | @ MALLINCKRODT HOSP | 100PPM | N020845 | 002 | Dec 23, 1999 | Jan | CAHN | |
| >A> | | + | 800PPM | N020845 | 003 | Dec 23, 1999 | Jan | CAHN | |
| <u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u> | | | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | MACROBID | | | | | | | |
| >D> | AB | + ALVOGEN INC | 75MG;25MG | N020064 | 001 | Dec 24, 1991 | Jan | CAHN | |
| >A> | AB | + ALVOGEN MALTA | 75MG;25MG | N020064 | 001 | Dec 24, 1991 | Jan | CAHN | |
| <u>NOREPINEPHRINE BITARTRATE</u> | | | | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | | |
| | | NOREPINEPHRINE BITARTRATE | | | | | | | |
| >A> | AP | CLARIS | EQ 1MG BASE/ML | A040859 | 001 | Mar 27, 2012 | Jan | CAHN | |
| >D> | AP | CLARIS LIFESCIENCES | EQ 1MG BASE/ML | A040859 | 001 | Mar 27, 2012 | Jan | CAHN | |
| <u>NORETHINDRONE</u> | | | | | | | | | |
| | | TABLET;ORAL-28 | | | | | | | |
| | | NOR-QD | | | | | | | |
| >D> | AB1 | + ACTAVIS LABS UT INC | 0.35MG | N017060 | 001 | | Jan | CAHN | |
| >A> | AB1 | + ALLERGAN PHARMS INTL | 0.35MG | N017060 | 001 | | Jan | CAHN | |
| <u>OCTREOTIDE ACETATE</u> | | | | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | | |
| | | OCTREOTIDE ACETATE | | | | | | | |
| >D> | AP | WOCKHARDT USA | EQ 0.2MG BASE/ML | A090986 | 001 | May 11, 2011 | Jan | DISC | |
| >A> | | @ | EQ 0.2MG BASE/ML | A090986 | 001 | May 11, 2011 | Jan | DISC | |
| >D> | AP | | EQ 1MG BASE/ML | A090986 | 002 | May 11, 2011 | Jan | DISC | |
| >A> | | @ | EQ 1MG BASE/ML | A090986 | 002 | May 11, 2011 | Jan | DISC | |
| | | OCTREOTIDE ACETATE (PRESERVATIVE FREE) | | | | | | | |
| >D> | AP | WOCKHARDT USA | EQ 0.05MG BASE/ML | A090985 | 001 | May 11, 2011 | Jan | DISC | |
| >A> | | @ | EQ 0.05MG BASE/ML | A090985 | 001 | May 11, 2011 | Jan | DISC | |
| >D> | AP | | EQ 0.1MG BASE/ML | A090985 | 002 | May 11, 2011 | Jan | DISC | |
| >A> | | @ | EQ 0.1MG BASE/ML | A090985 | 002 | May 11, 2011 | Jan | DISC | |
| >D> | AP | | EQ 0.5MG BASE/ML | A090985 | 003 | May 11, 2011 | Jan | DISC | |
| >A> | | @ | EQ 0.5MG BASE/ML | A090985 | 003 | May 11, 2011 | Jan | DISC | |
| <u>OLANZAPINE</u> | | | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | OLANZAPINE | | | | | | | |
| >A> | AB | QILU PHARM CO LTD | 2.5MG | A204319 | 001 | Jan 27, 2016 | Jan | NEWA | |
| >A> | AB | | 5MG | A204319 | 002 | Jan 27, 2016 | Jan | NEWA | |
| >A> | AB | | 7.5MG | A204319 | 003 | Jan 27, 2016 | Jan | NEWA | |

TABLET;ORAL
OLANZAPINE

| | | | | | | | |
|-----|----|--|------|---------|-----|--------------|----------|
| >A> | AB | | 10MG | A204319 | 004 | Jan 27, 2016 | Jan NEWA |
| >A> | AB | | 15MG | A204319 | 005 | Jan 27, 2016 | Jan NEWA |
| >A> | AB | | 20MG | A204319 | 006 | Jan 27, 2016 | Jan NEWA |

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

| | | | | | | | |
|-----|----|---------------|---|---------|-----|--------------|----------|
| >D> | AB | AMNEAL PHARMS | 1 GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A204940 | 001 | Nov 27, 2015 | Jan CMS1 |
| >A> | AB | | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A204940 | 001 | Nov 27, 2015 | Jan CMS1 |

OXALIPLATIN

INJECTABLE;IV (INFUSION)
OXALIPLATIN

| | | | | | | | |
|-----|----|--------------|---------------------|---------|-----|--------------|----------|
| >D> | AP | EBEWE PHARMA | 50MG/10ML (5MG/ML) | A078812 | 001 | Aug 07, 2009 | Jan CAHN |
| >D> | AP | | 100MG/20ML (5MG/ML) | A078812 | 002 | Aug 07, 2009 | Jan CAHN |
| >A> | AP | SANDOZ INC | 50MG/10ML (5MG/ML) | A078812 | 001 | Aug 07, 2009 | Jan CAHN |
| >A> | AP | | 100MG/20ML (5MG/ML) | A078812 | 002 | Aug 07, 2009 | Jan CAHN |

OXYCODONE HYDROCHLORIDE

TABLET;ORAL
OXYCODONE HYDROCHLORIDE

| | | | | | | | |
|-----|----|---------------|------|---------|-----|--------------|----------|
| >D> | AB | ALVOGEN INC | 5MG | A202116 | 001 | Dec 30, 2011 | Jan CAHN |
| >D> | AB | | 15MG | A202116 | 002 | Dec 30, 2011 | Jan CAHN |
| >D> | AB | | 30MG | A202116 | 003 | Dec 30, 2011 | Jan CAHN |
| >A> | AB | ALVOGEN MALTA | 5MG | A202116 | 001 | Dec 30, 2011 | Jan CAHN |
| >A> | AB | | 15MG | A202116 | 002 | Dec 30, 2011 | Jan CAHN |
| >A> | AB | | 30MG | A202116 | 003 | Dec 30, 2011 | Jan CAHN |

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

| | | | | | | | |
|-----|----|--------------|--------|---------|-----|--------------|----------|
| >D> | AP | EBEWE PHARMA | 6MG/ML | A078167 | 001 | Dec 26, 2007 | Jan CAHN |
| >A> | AP | SANDOZ INC | 6MG/ML | A078167 | 001 | Dec 26, 2007 | Jan CAHN |

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

| | | | | | | | |
|-----|----|----------------|--------------------|---------|-----|--------------|----------|
| >D> | AP | MUSTAFA NEVZAT | 30MG/10ML (3MG/ML) | A078373 | 001 | Dec 23, 2008 | Jan CAHN |
| >D> | AP | | 90MG/10ML (9MG/ML) | A078373 | 002 | Dec 23, 2008 | Jan CAHN |
| >A> | AP | SAGENT PHARMS | 30MG/10ML (3MG/ML) | A078373 | 001 | Dec 23, 2008 | Jan CAHN |
| >A> | AP | | 90MG/10ML (9MG/ML) | A078373 | 002 | Dec 23, 2008 | Jan CAHN |

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

| | | | | | | | |
|-----|----|---------------|--------------|---------|-----|--------------|----------|
| >A> | AB | AMNEAL PHARMS | EQ 20MG BASE | A205119 | 001 | Jan 26, 2016 | Jan NEWA |
| >A> | AB | | EQ 40MG BASE | A205119 | 002 | Jan 26, 2016 | Jan NEWA |

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

| | | | | | | | |
|-----|----|----------------------|------|---------|-----|--------------|----------|
| >D> | AB | BANNER LIFE SCIENCES | 1MCG | A202539 | 001 | Mar 27, 2014 | Jan CAHN |
| >D> | AB | | 2MCG | A202539 | 002 | Mar 27, 2014 | Jan CAHN |
| >D> | AB | | 4MCG | A202539 | 003 | Mar 27, 2014 | Jan CAHN |
| >A> | AB | BIONPHARMA INC | 1MCG | A202539 | 001 | Mar 27, 2014 | Jan CAHN |
| >A> | AB | | 2MCG | A202539 | 002 | Mar 27, 2014 | Jan CAHN |
| >A> | AB | | 4MCG | A202539 | 003 | Mar 27, 2014 | Jan CAHN |

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
TRENENTAL

| | | | | | | | |
|-----|--|---------------------|-------|---------|-----|--------------|----------|
| >D> | | @ SANOFI AVENTIS US | 400MG | N018631 | 001 | Aug 30, 1984 | Jan CAHN |
| >A> | | @ US PHARM HOLDINGS | 400MG | N018631 | 001 | Aug 30, 1984 | Jan CAHN |

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

| | | | | | | | | |
|-----|----|---------------------|------|---------|-----|--------------|-----|------|
| >D> | AB | INDICUS PHARMA | 2MG | A205973 | 001 | Dec 17, 2015 | Jan | CAHN |
| >D> | AB | | 4MG | A205973 | 002 | Dec 17, 2015 | Jan | CAHN |
| >D> | AB | | 8MG | A205973 | 003 | Dec 17, 2015 | Jan | CAHN |
| >D> | AB | | 16MG | A205973 | 004 | Dec 17, 2015 | Jan | CAHN |
| >A> | AB | WILSHIRE PHARMS INC | 2MG | A205973 | 001 | Dec 17, 2015 | Jan | CAHN |
| >A> | AB | | 4MG | A205973 | 002 | Dec 17, 2015 | Jan | CAHN |
| >A> | AB | | 8MG | A205973 | 003 | Dec 17, 2015 | Jan | CAHN |
| >A> | AB | | 16MG | A205973 | 004 | Dec 17, 2015 | Jan | CAHN |

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE

| | | | | | | | | |
|-----|---|------|-------------------------------|---------|-----|--------------|-----|------|
| >D> | @ | ABLE | 200MG,N/A,N/A;N/A,800MG,160MG | N021105 | 001 | Jun 26, 2001 | Jan | CMS1 |
| >A> | @ | ABLE | 200MG,N/A,N/A;N/A,800MG,160MG | N021105 | 001 | Jun 26, 2001 | Jan | CMS1 |

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------------|--------|---------|-----|--------------|-----|------|
| >A> | AA | INGENUS PHARMS NJ | 37.5MG | A091451 | 001 | Sep 21, 2012 | Jan | CAHN |
| >D> | AA | MIRROR PHARMS | 37.5MG | A091451 | 001 | Sep 21, 2012 | Jan | CAHN |

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

| | | | | | | | | |
|-----|---|---------------------|-----------|---------|-----|--|-----|------|
| >D> | @ | IGI LABS INC | 1MG/0.5ML | N012223 | 002 | | Jan | CAHN |
| >D> | @ | | 10MG/ML | N012223 | 001 | | Jan | CAHN |
| >A> | @ | TELIGENT PHARMA INC | 1MG/0.5ML | N012223 | 002 | | Jan | CAHN |
| >A> | @ | | 10MG/ML | N012223 | 001 | | Jan | CAHN |

PIROXICAM

CAPSULE;ORAL

PIROXICAM

| | | | | | | | | |
|-----|----|------------------|------|---------|-----|--------------|-----|------|
| >D> | AB | MYLAN PHARMS INC | 20MG | A074118 | 001 | Jun 15, 1993 | Jan | CAHN |
| >A> | AB | | 20MG | A074118 | 001 | Jun 15, 1993 | Jan | CAHN |

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

| | | | | | | | | |
|-----|-----|---------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | GLENMARK PHARMS LTD | 10MEQ | A202868 | 001 | Jan 19, 2016 | Jan | NEWA |
| >A> | AB1 | NOVEL LABS INC | 10MEQ | A206347 | 001 | Jan 21, 2016 | Jan | NEWA |
| >A> | AB1 | | 20MEQ | A206347 | 002 | Jan 21, 2016 | Jan | NEWA |

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | BANNER LIFE SCIENCES | 100MG | A200900 | 001 | Aug 16, 2013 | Jan | CAHN |
| >D> | AB | | 200MG | A200900 | 002 | Aug 16, 2013 | Jan | CAHN |
| >A> | AB | BIONPHARMA INC | 100MG | A200900 | 001 | Aug 16, 2013 | Jan | CAHN |
| >A> | AB | | 200MG | A200900 | 002 | Aug 16, 2013 | Jan | CAHN |

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

| | | | | | | | | |
|-----|---|----------------|------|---------|-----|--|-----|------|
| >D> | @ | MUTUAL PHARM | 50MG | A084557 | 001 | | Jan | CAHN |
| >A> | @ | SUN PHARM INDS | 50MG | A084557 | 001 | | Jan | CAHN |

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

| | | | | | | | | |
|-----|----|---------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | ALVOGEN INC | 180MG | A204737 | 001 | Jun 26, 2015 | Jan | CAHN |
| >A> | AB | ALVOGEN MALTA | 180MG | A204737 | 001 | Jun 26, 2015 | Jan | CAHN |

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

| | | | | | | | |
|-----|----|---------------------|--------------|---------|-----|--------------|----------|
| >D> | AB | ACTAVIS LABS FL INC | EQ 5MG BASE | A076049 | 001 | Jan 14, 2005 | Jan DISC |
| >A> | | @ | EQ 5MG BASE | A076049 | 001 | Jan 14, 2005 | Jan DISC |
| >D> | AB | | EQ 10MG BASE | A076049 | 002 | Jan 14, 2005 | Jan DISC |
| >A> | | @ | EQ 10MG BASE | A076049 | 002 | Jan 14, 2005 | Jan DISC |
| >D> | AB | | EQ 20MG BASE | A076049 | 003 | Jan 14, 2005 | Jan DISC |
| >A> | | @ | EQ 20MG BASE | A076049 | 003 | Jan 14, 2005 | Jan DISC |
| >D> | AB | | EQ 40MG BASE | A076049 | 004 | Jan 14, 2005 | Jan DISC |
| >A> | | @ | EQ 40MG BASE | A076049 | 004 | Jan 14, 2005 | Jan DISC |

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

| | | | | | | | |
|-----|----|-----------------------------|--------------------|---------|-----|--------------|----------|
| >D> | AP | + CONCORDIA PHARMS INC | EQ 25MG BASE/ML | N019090 | 001 | Oct 19, 1984 | Jan CAHN |
| >A> | AP | + IGI LABS INC | EQ 25MG BASE/ML | N019090 | 001 | Oct 19, 1984 | Jan CAHN |
| | | ZANTAC IN PLASTIC CONTAINER | | | | | |
| >D> | | @ COVIS INJECTABLES | EQ 1MG BASE/ML | N019593 | 002 | Sep 27, 1991 | Jan CAHN |
| >D> | | @ | EQ 50MG BASE/100ML | N019593 | 001 | Dec 17, 1986 | Jan CAHN |
| >A> | | @ IGI LABS INC | EQ 1MG BASE/ML | N019593 | 002 | Sep 27, 1991 | Jan CAHN |
| >A> | | @ | EQ 50MG BASE/100ML | N019593 | 001 | Dec 17, 1986 | Jan CAHN |

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

| | | | | | | | |
|-----|--|-------------------|----|---------|-----|--------------|----------|
| >A> | | + AQUA PHARMS LLC | 1% | N022055 | 001 | Apr 12, 2007 | Jan CAHN |
| >D> | | + GLAXO GRP LTD | 1% | N022055 | 001 | Apr 12, 2007 | Jan CAHN |

RIFAMPIN

INJECTABLE;INJECTION

RIFAMPIN

| | | | | | | | |
|-----|----|-------------------|------------|---------|-----|--------------|----------|
| >A> | AP | WATSON PHARMS INC | 600MG/VIAL | A206736 | 001 | Jan 19, 2016 | Jan NEWA |
|-----|----|-------------------|------------|---------|-----|--------------|----------|

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

| | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|----------|
| >A> | AB | ALLERGAN PHARMS INTL | 5MG | N020835 | 002 | Apr 14, 2000 | Jan CAHN |
| >A> | AB | | 30MG | N020835 | 001 | Mar 27, 1998 | Jan CAHN |
| >A> | AB | + | 35MG | N020835 | 003 | May 25, 2002 | Jan CAHN |
| >A> | | @ | 75MG | N020835 | 004 | Apr 16, 2007 | Jan CAHN |
| >A> | AB | + | 150MG | N020835 | 005 | Apr 22, 2008 | Jan CAHN |
| >D> | AB | WARNER CHILCOTT LLC | 5MG | N020835 | 002 | Apr 14, 2000 | Jan CAHN |
| >D> | AB | | 30MG | N020835 | 001 | Mar 27, 1998 | Jan CAHN |
| >D> | AB | + | 35MG | N020835 | 003 | May 25, 2002 | Jan CAHN |
| >D> | | @ | 75MG | N020835 | 004 | Apr 16, 2007 | Jan CAHN |
| >D> | AB | + | 150MG | N020835 | 005 | Apr 22, 2008 | Jan CAHN |

TABLET, DELAYED RELEASE;ORAL

ATELVIA

| | | | | | | | |
|-----|----|------------------------|------|---------|-----|--------------|----------|
| >A> | AB | + ALLERGAN PHARMS INTL | 35MG | N022560 | 001 | Oct 08, 2010 | Jan CAHN |
| >D> | AB | + WARNER CHILCOTT LLC | 35MG | N022560 | 001 | Oct 08, 2010 | Jan CAHN |

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

| | | | | | | | |
|-----|----|--------------------|-------------|---------|-----|--------------|----------|
| >A> | AB | ALVOGEN MALTA | 4.6MG/24HR | A204403 | 001 | Sep 03, 2015 | Jan CAHN |
| >A> | AB | | 9.5MG/24HR | A204403 | 002 | Sep 03, 2015 | Jan CAHN |
| >A> | AB | | 13.3MG/24HR | A204403 | 003 | Aug 31, 2015 | Jan CAHN |
| >D> | AB | ALVOGEN PINE BROOK | 4.6MG/24HR | A204403 | 001 | Sep 03, 2015 | Jan CAHN |
| >D> | AB | | 9.5MG/24HR | A204403 | 002 | Sep 03, 2015 | Jan CAHN |
| >D> | AB | | 13.3MG/24HR | A204403 | 003 | Aug 31, 2015 | Jan CAHN |

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

| | | | | | | | |
|-----|----|----------|-------------|---------|-----|--------------|----------|
| >D> | AB | NOVARTIS | EQ 6MG BASE | N020823 | 006 | Apr 21, 2000 | Jan CRLD |
| >A> | AB | + | EQ 6MG BASE | N020823 | 006 | Apr 21, 2000 | Jan CRLD |

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

| | | | | | | | |
|-----|----|-------------------|--------------|---------|-----|--------------|----------|
| >A> | AB | NOSTRUM LABS INC | EQ 5MG BASE | A202047 | 001 | Dec 31, 2012 | Jan CAHN |
| >A> | AB | | EQ 10MG BASE | A202047 | 002 | Dec 31, 2012 | Jan CAHN |
| >D> | AB | SUN PHARMA GLOBAL | EQ 5MG BASE | A202047 | 001 | Dec 31, 2012 | Jan CAHN |
| >D> | AB | | EQ 10MG BASE | A202047 | 002 | Dec 31, 2012 | Jan CAHN |

SUCRALFATE

TABLET;ORAL

SUCRALFATE

| | | | | | | | |
|-----|----|-------------------|-----|---------|-----|--------------|----------|
| >A> | AB | MYLAN IRELAND LTD | 1GM | A074415 | 001 | Jun 08, 1998 | Jan CAHN |
| >D> | AB | MYLAN PHARMS INC | 1GM | A074415 | 001 | Jun 08, 1998 | Jan CAHN |

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

| | | | | | | | |
|-----|---|-------------------|---|---------|-----|--------------|----------|
| >D> | | ORGANON SUB MERCK | 200MG/2ML (100MG/ML) | N022225 | 002 | Dec 15, 2015 | Jan CPOT |
| >A> | | | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | N022225 | 002 | Dec 15, 2015 | Jan CPOT |
| >D> | + | | 500MG/5ML (100MG/ML) | N022225 | 001 | Dec 15, 2015 | Jan CPOT |
| >A> | + | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | N022225 | 001 | Dec 15, 2015 | Jan CPOT |

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

| | | | | | | | |
|-----|--|------------------|--------------------|---------|-----|--------------|----------|
| >A> | | @ ANI PHARMS INC | 200MG/5ML;40MG/5ML | A077612 | 001 | Nov 13, 2006 | Jan CAHN |
| >D> | | @ TEVA PHARMS | 200MG/5ML;40MG/5ML | A077612 | 001 | Nov 13, 2006 | Jan CAHN |

SUMATRIPTAN SUCCINATE

| | | | | | | | |
|-----|---|-----------------------|--|---------|-----|--------------|----------|
| >A> | | POWDER;INHALATION | | | | | |
| >A> | | ONZETRA XSAIL | | | | | |
| >A> | + | AVANIR PHARMS | EQ 11MG BASE | N206099 | 001 | Jan 27, 2016 | Jan NEWA |
| >A> | | SOLUTION;SUBCUTANEOUS | | | | | |
| >A> | | ZEMBRACE SYMTOUCH | | | | | |
| >A> | | DR REDDYS LABS LTD | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | N208223 | 001 | Jan 28, 2016 | Jan NEWA |

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

| | | | | | | | |
|-----|--|--------------------|------------------|---------|-----|--------------|----------|
| >D> | | DARA BIOSCIENCES | EQ 10MG BASE/5ML | N021807 | 001 | Oct 29, 2005 | Jan CAHN |
| >A> | | MIDATECH PHARMA US | EQ 10MG BASE/5ML | N021807 | 001 | Oct 29, 2005 | Jan CAHN |

TABLET;ORAL

TAMOXIFEN CITRATE

| | | | | | | | |
|-----|----|---------------------|--------------|---------|-----|--------------|----------|
| >D> | AB | ACTAVIS LABS FL INC | EQ 10MG BASE | A076179 | 001 | Feb 20, 2003 | Jan DISC |
| >A> | | @ | EQ 10MG BASE | A076179 | 001 | Feb 20, 2003 | Jan DISC |
| >A> | | @ | EQ 20MG BASE | A076179 | 002 | Feb 20, 2003 | Jan DISC |
| >D> | AB | WATSON LABS FLORIDA | EQ 20MG BASE | A076179 | 002 | Feb 20, 2003 | Jan DISC |

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW FM

| | | | | | | | |
|-----|---|---------------------|---------------------|---------|-----|--------------|----------|
| >D> | + | MALLINCKRODT | 1-19 CI/GENERATOR | N017243 | 003 | Feb 18, 2014 | Jan CAHN |
| >D> | | @ | 0.25-3 CI/GENERATOR | N017243 | 002 | | Jan CAHN |
| >A> | + | MALLINKRODT NUCLEAR | 1-19 CI/GENERATOR | N017243 | 003 | Feb 18, 2014 | Jan CAHN |
| >A> | | @ | 0.25-3 CI/GENERATOR | N017243 | 002 | | Jan CAHN |

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

| | | | | | | | |
|-----|--|--------------------|-------------|---------|-----|--------------|----------|
| >D> | | @ NOVARTIS | EQ 2MG BASE | N021200 | 001 | Jul 24, 2002 | Jan CAHN |
| >D> | | @ | EQ 6MG BASE | N021200 | 002 | Jul 24, 2002 | Jan CAHN |
| >A> | | @ US WORLDMEDS LLC | EQ 2MG BASE | N021200 | 001 | Jul 24, 2002 | Jan CAHN |
| >A> | | @ | EQ 6MG BASE | N021200 | 002 | Jul 24, 2002 | Jan CAHN |

TEMOZOLOMIDE

CAPSULE;ORAL
TEMOZOLOMIDE

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | KREMERS URBAN PHARMS | 5MG | A203898 | 001 | Feb 10, 2016 | Jan | NEWA |
| >A> | AB | | 20MG | A203898 | 002 | Feb 10, 2016 | Jan | NEWA |
| >A> | AB | | 100MG | A203898 | 003 | Feb 10, 2016 | Jan | NEWA |
| >A> | AB | | 140MG | A203898 | 004 | Feb 10, 2016 | Jan | NEWA |
| >A> | AB | | 180MG | A203898 | 005 | Feb 10, 2016 | Jan | NEWA |
| >A> | AB | | 250MG | A203898 | 006 | Feb 10, 2016 | Jan | NEWA |

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

| | | | | | | | | |
|-----|----|-------------------|--------|---------|-----|--------------|-----|------|
| >A> | AB | HETERO LABS LTD V | 12.5MG | A204574 | 001 | Feb 03, 2016 | Jan | NEWA |
| >A> | AB | | 25MG | A204574 | 002 | Feb 03, 2016 | Jan | NEWA |

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

| | | | | | | | | |
|-----|---|--------------------|-----------|---------|-----|--|-----|------|
| >A> | + | NOSTRUM LABS INC | 80MG/15ML | A085186 | 001 | | Jan | CAHN |
| >D> | + | SUN PHARM INDS INC | 80MG/15ML | A085186 | 001 | | Jan | CAHN |

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

| | | | | | | | | |
|-----|----|--------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | NOSTRUM LABS INC | 100MG | A088320 | 001 | Feb 21, 1985 | Jan | CAHN |
| >A> | AB | | 200MG | A088321 | 001 | Feb 21, 1985 | Jan | CAHN |
| >A> | @ | | 300MG | A087400 | 002 | Jan 11, 1983 | Jan | CAHN |
| >D> | AB | SUN PHARM INDS INC | 100MG | A088320 | 001 | Feb 21, 1985 | Jan | CAHN |
| >D> | AB | | 200MG | A088321 | 001 | Feb 21, 1985 | Jan | CAHN |
| >D> | @ | | 300MG | A087400 | 002 | Jan 11, 1983 | Jan | CAHN |

THEOPHYLLINE

| | | | | | | | | |
|-----|----|-------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | MYLAN IRELAND LTD | 400MG | A040560 | 003 | Apr 21, 2006 | Jan | CAHN |
| >A> | AB | + | 600MG | A040560 | 002 | Apr 21, 2006 | Jan | CAHN |
| >D> | AB | MYLAN PHARMS INC | 400MG | A040560 | 003 | Apr 21, 2006 | Jan | CAHN |
| >D> | AB | + | 600MG | A040560 | 002 | Apr 21, 2006 | Jan | CAHN |

TOPIRAMATE

TABLET;ORAL
TOPIRAMATE

| | | | | | | | | |
|-----|----|--------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | ACTAVIS TOTOWA | 25MG | A078637 | 001 | Feb 27, 2013 | Jan | CAHN |
| >A> | AB | | 50MG | A078637 | 002 | Feb 27, 2013 | Jan | CAHN |
| >A> | AB | | 100MG | A078637 | 003 | Feb 27, 2013 | Jan | CAHN |
| >A> | AB | | 200MG | A078637 | 004 | Feb 27, 2013 | Jan | CAHN |
| >D> | AB | ACTIVIS TOTOWA LLC | 25MG | A078637 | 001 | Feb 27, 2013 | Jan | CAHN |
| >D> | AB | | 50MG | A078637 | 002 | Feb 27, 2013 | Jan | CAHN |
| >D> | AB | | 100MG | A078637 | 003 | Feb 27, 2013 | Jan | CAHN |
| >D> | AB | | 200MG | A078637 | 004 | Feb 27, 2013 | Jan | CAHN |

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

| | | | | | | | | |
|-----|----|----------------------|----------|---------|-----|--------------|-----|------|
| >A> | AP | AUROBINDO PHARMA LTD | 100MG/ML | A205035 | 001 | Jan 14, 2016 | Jan | NEWA |
|-----|----|----------------------|----------|---------|-----|--------------|-----|------|

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL
PRIMSOL

| | | | | | | | | |
|-----|---|-------------|------------------|---------|-----|--------------|-----|------|
| >A> | @ | AYTU PHARMS | EQ 25MG BASE/5ML | A074374 | 001 | Jun 23, 1995 | Jan | CAHN |
| >A> | + | | EQ 50MG BASE/5ML | N074973 | 001 | Jan 24, 2000 | Jan | CAHN |
| >D> | @ | FSC | EQ 25MG BASE/5ML | A074374 | 001 | Jun 23, 1995 | Jan | CAHN |
| >D> | + | | EQ 50MG BASE/5ML | N074973 | 001 | Jan 24, 2000 | Jan | CAHN |

VALPROIC ACID

CAPSULE;ORAL
VALPROIC ACID

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | BANNER LIFE SCIENCES | 250MG | A073484 | 001 | Jun 29, 1993 | Jan | CAHN |
| >A> | AB | BIONPHARMA INC | 250MG | A073484 | 001 | Jun 29, 1993 | Jan | CAHN |

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

| | | | | | | | | |
|-----|---|----------------------|-------|---------|-----|--------------|-----|------|
| >D> | @ | BANNER LIFE SCIENCES | 125MG | N022152 | 001 | Jul 29, 2008 | Jan | CAHN |
| >D> | @ | | 250MG | N022152 | 002 | Jul 29, 2008 | Jan | CAHN |
| >D> | @ | | 500MG | N022152 | 003 | Jul 29, 2008 | Jan | CAHN |
| >A> | @ | BIONPHARMA INC | 125MG | N022152 | 001 | Jul 29, 2008 | Jan | CAHN |

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

| | | | | | | |
|-----|---|-------|---------|-----|--------------|----------|
| >A> | @ | 250MG | N022152 | 002 | Jul 29, 2008 | Jan CAHN |
| >A> | @ | 500MG | N022152 | 003 | Jul 29, 2008 | Jan CAHN |

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

| | | | | | | | |
|-----|----|------------------|--------------------|---------|-----|--------------|----------|
| >A> | AP | GLAND PHARMA LTD | EQ 500MG BASE/VIAL | A205694 | 001 | Jan 21, 2016 | Jan NEWA |
| >A> | AP | | EQ 1GM BASE/VIAL | A205694 | 002 | Jan 21, 2016 | Jan NEWA |

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

| | | | | | | | |
|-----|----|----------------|-----------|---------|-----|--------------|----------|
| >D> | AP | MUSTAFA NEVZAT | 10MG/VIAL | A078274 | 001 | Dec 29, 2008 | Jan CAHN |
| >D> | AP | | 20MG/VIAL | A078274 | 002 | Dec 29, 2008 | Jan CAHN |
| >A> | AP | SAGENT PHARMS | 10MG/VIAL | A078274 | 001 | Dec 29, 2008 | Jan CAHN |
| >A> | AP | | 20MG/VIAL | A078274 | 002 | Dec 29, 2008 | Jan CAHN |

VORICONAZOLE

TABLET; ORAL
VORICONAZOLE

| | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|----------|
| >A> | AB | AUROBINDO PHARMA LTD | 50MG | A206837 | 001 | Jan 22, 2016 | Jan NEWA |
| >A> | AB | | 200MG | A206837 | 002 | Jan 22, 2016 | Jan NEWA |

ZONISAMIDE

CAPSULE; ORAL
ZONISAMIDE

| | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|----------|
| >D> | AB | BANNER LIFE SCIENCES | 25MG | A077813 | 001 | Aug 16, 2006 | Jan CAHN |
| >D> | AB | | 50MG | A077813 | 002 | Aug 16, 2006 | Jan CAHN |
| >D> | AB | | 100MG | A077813 | 003 | Aug 16, 2006 | Jan CAHN |
| >A> | AB | BIONPHARMA INC | 25MG | A077813 | 001 | Aug 16, 2006 | Jan CAHN |
| >A> | AB | | 50MG | A077813 | 002 | Aug 16, 2006 | Jan CAHN |
| >A> | AB | | 100MG | A077813 | 003 | Aug 16, 2006 | Jan CAHN |

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

| | | | | | | | |
|-----|---|---------------------------------------|------|---------|-----|--------------|----------|
| >D> | | BANNER LIFE SCIENCES | 5MG | N022429 | 001 | Jul 23, 2009 | Jan CAHN |
| >D> | + | | 10MG | N022429 | 004 | Jul 23, 2009 | Jan CAHN |
| >A> | | BIONPHARMA INC | 5MG | N022429 | 001 | Jul 23, 2009 | Jan CAHN |
| >A> | + | | 10MG | N022429 | 004 | Jul 23, 2009 | Jan CAHN |
| | | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | | | | | |
| >D> | | BANNER LIFE SCIENCES | 5MG | N022429 | 003 | Jul 23, 2009 | Jan CAHN |
| >D> | + | | 10MG | N022429 | 002 | Jul 23, 2009 | Jan CAHN |
| >A> | | BIONPHARMA INC | 5MG | N022429 | 003 | Jul 23, 2009 | Jan CAHN |
| >A> | + | | 10MG | N022429 | 002 | Jul 23, 2009 | Jan CAHN |

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | |
|-----|--|----------------------|--|---------|-----|--------------|----------|
| >D> | | BANNER LIFE SCIENCES | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | A090397 | 001 | Nov 22, 2010 | Jan CAHN |
| >A> | | BIONPHARMA INC | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | A090397 | 001 | Nov 22, 2010 | Jan CAHN |

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

| | | | | | | | |
|-----|---|----------------------|---------------------------------------|---------|-----|--------------|----------|
| >D> | | BANNER LIFE SCIENCES | EQ 200MG FREE ACID AND POTASSIUM SALT | A078682 | 001 | Mar 24, 2009 | Jan CAHN |
| >A> | | BIONPHARMA INC | EQ 200MG FREE ACID AND POTASSIUM SALT | A078682 | 001 | Mar 24, 2009 | Jan CAHN |
| | | MIDOL LIQUID GELS | | | | | |
| >D> | + | BANNER LIFE SCIENCES | 200MG | N021472 | 001 | Oct 18, 2002 | Jan CAHN |
| >A> | + | BIONPHARMA INC | 200MG | N021472 | 001 | Oct 18, 2002 | Jan CAHN |

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

| | | | | | | | |
|-----|---|----------------------|-----|---------|-----|--------------|----------|
| >D> | | BANNER LIFE SCIENCES | 1MG | N021855 | 001 | Aug 04, 2005 | Jan CAHN |
| >D> | + | | 2MG | N021855 | 002 | Aug 04, 2005 | Jan CAHN |
| >A> | | BIONPHARMA INC | 1MG | N021855 | 001 | Aug 04, 2005 | Jan CAHN |
| >A> | + | | 2MG | N021855 | 002 | Aug 04, 2005 | Jan CAHN |

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

| | | | | | | | |
|-----|---|----------------------|------------|---------|-----|--------------|----------|
| >A> | + | ALLERGAN SALES LLC | 3.9MG/24HR | N202211 | 001 | Jan 25, 2013 | Jan CAHN |
| >D> | + | BAYER HEALTHCARE LLC | 3.9MG/24HR | N202211 | 001 | Jan 25, 2013 | Jan CAHN |

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 01 JANUARY 2016

NO JANUARY 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JANUARY 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------|--------------|-------------------------|----------------------|-----------------------------|
| <u>ACETYLCYSTEINE - CETYLEV</u> | | | | | | |
| N 207916 001 | >A> 8747894 | May 08, 2032 | DP U-1373 | | | |
| <u>ACETYLCYSTEINE - CETYLEV</u> | | | | | | |
| N 207916 002 | >A> 8747894 | May 08, 2032 | DP U-1373 | | | |
| <u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u> | | | | | | |
| N 207917 001 | >A> 8809305 | Dec 23, 2022 | U-1078 | | | |
| <u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u> | | | | | | |
| N 205636 001 | >A> 8978966 | Jan 13, 2032 | DP | | | |
| | >A> 9216260 | Jun 28, 2031 | DP | | | |
| <u>BALSALAZIDE DISODIUM - GIAZO</u> | | | | | | |
| N 022205 001 | >A> 9192616 | Aug 02, 2026 | U-1229 | | | |
| <u>BIMATOPROST - LATISSE</u> | | | | | | |
| N 022369 001 | >A> 9216183 | Jan 15, 2023 | U-1487 | | | |
| | >A> 9226931 | Jan 15, 2023 | U-1799 | | | |
| <u>CARFILZOMIB - KYPROLIS</u> | | | | | | |
| N 202714 001 | | | | >A> I-722 | | Jan 21, 2019 |
| | | | | >A> I-723 | | Jan 21, 2019 |
| <u>CEFIXIME - SUPRAX</u> | | | | | | |
| N 202091 001 | >A> 9233112 | Dec 14, 2028 | DP U-1676 | | | |
| <u>CIPROFLOXACIN - OTIPRIO</u> | | | | | | |
| N 207986 001 | >A> 9233068 | Dec 11, 2029 | DP | >A> NP | | Dec 10, 2018 |
| <u>CYCLOSPORINE - RESTASIS</u> | | | | | | |
| N 050790 001 | >A> 9248191 | Aug 27, 2024 | U-1479 | | | |
| <u>CYSTEAMINE BITARTRATE - PROCYSBI</u> | | | | | | |
| N 203389 001 | >A> 9233077 | Jun 17, 2034 | DP | | | |
| <u>CYSTEAMINE BITARTRATE - PROCYSBI</u> | | | | | | |
| N 203389 002 | >A> 9233077 | Jun 17, 2034 | DP | | | |
| <u>DABRAFENIB MESYLATE - TAFINLAR</u> | | | | | | |
| N 202806 001 | | | | >A> M-170 | | Nov 20, 2018 |
| <u>DABRAFENIB MESYLATE - TAFINLAR</u> | | | | | | |
| N 202806 002 | | | | >A> M-170 | | Nov 20, 2018 |
| <u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u> | | | | | | |
| N 021883 001 | | | | >A> D-154 | | Jan 20, 2019 |
| <u>DEFERASIROX - JADENU</u> | | | | | | |
| N 206910 001 | | | | >A> ODE | | Jan 23, 2020 |
| <u>DEFERASIROX - JADENU</u> | | | | | | |
| N 206910 002 | | | | >A> ODE | | Jan 23, 2020 |
| <u>DEFERASIROX - JADENU</u> | | | | | | |
| N 206910 003 | | | | >A> ODE | | Jan 23, 2020 |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>DICLOFENAC SODIUM - PENNSAID</u> | | | | | | |
| N 204623 001 | >A> 9220784 | Oct 17, 2027 | U-1488 | | | |
| <u>DOXYCYCLINE - ORACEA</u> | | | | | | |
| N 050805 001 | >A> 9241946 | Apr 05, 2022 | U-1063 | | | |
| <u>ELBASVIR; GRAZOPREVR - ZEPATIER</u> | | | | | | |
| N 208261 001 | | | | | >A> NCE | Jan 28, 2021 |
| <u>EPINEPHRINE - ADRENALIN</u> | | | | | | |
| N 204200 001 | >A> 9119876 | Mar 13, 2035 | DP | | | |
| <u>ERIBULIN MESYLATE - HALAVEN</u> | | | | | | |
| N 201532 001 | | | | | >A> I-721 | Jan 28, 2019 |
| <u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u> | | | | | | |
| N 022511 001 | >A> 9220698 | Mar 10, 2031 | U-1781 | | | |
| <u>IMATINIB MESYLATE - IMATINIB MESYLATE</u> | | | | | | |
| A 078340 001 | | | | | >A> PC | Jul 30, 2016 |
| <u>IMATINIB MESYLATE - IMATINIB MESYLATE</u> | | | | | | |
| A 078340 002 | | | | | >A> PC | Jul 30, 2016 |
| <u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u> | | | | | | |
| N 021081 002 | >A> 9233211 | Mar 02, 2024 | DP | | | |
| <u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u> | | | | | | |
| N 206538 001 | >A> 9233211 | Mar 02, 2024 | DP | | | |
| <u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u> | | | | | | |
| N 021629 003 | >A> 9233211 | Mar 02, 2024 | DP | | | |
| <u>INSULIN HUMAN - HUMULIN R</u> | | | | | | |
| N 018780 004 | >A> 7291132 | Aug 09, 2024 | DP | | | |
| <u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u> | | | | | | |
| N 207793 001 | | | | | >A> ODE | Oct 22, 2022 |
| <u>IVERMECTIN - SOOLANTRA</u> | | | | | | |
| N 206255 001 | >A> 9233117 | Mar 13, 2034 | U-1631 | | | |
| | >A> 9233118 | Mar 13, 2034 | U-1631 | | | |
| <u>IXAZOMIB CITRATE - NINLARO</u> | | | | | | |
| N 208462 001 | >A> 9233115 | Aug 12, 2024 | U-1778 | | | |
| <u>IXAZOMIB CITRATE - NINLARO</u> | | | | | | |
| N 208462 002 | >A> 9233115 | Aug 12, 2024 | U-1778 | | | |
| <u>IXAZOMIB CITRATE - NINLARO</u> | | | | | | |
| N 208462 003 | >A> 9233115 | Aug 12, 2024 | U-1778 | | | |
| <u>KETOROLAC TROMETHAMINE - ACULAR LS</u> | | | | | | |
| N 021528 001 | >A> 9216127 | May 28, 2024 | U-1800 | | | |
| <u>LESINURAD - ZURAMPIC</u> | | | | | | |
| N 207988 001 | >A> 8003681 | Aug 25, 2025 | DS | | | |
| | >A> 8084483 | Aug 17, 2029 | U-1801 | | | |
| | >A> 8283369 | Nov 26, 2028 | U-1802 | | | |
| | >A> 8283369 | Nov 26, 2028 | U-1804 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>LESINURAD - ZURAMPIC</u> | | | | | | |
| N 207988 001 | >A> 8357713 | Nov 26, 2028 | DP U-1801 | | | |
| | >A> 8357713 | Nov 26, 2028 | DP U-1802 | | | |
| | >A> 8357713 | Nov 26, 2028 | DP U-1803 | | | |
| | >A> 8546436 | Feb 29, 2032 | DS DP | | | |
| | >A> 8546437 | Apr 29, 2029 | U-1803 | | | |
| <u>LULICONAZOLE - LUZU</u> | | | | | | |
| N 204153 001 | >A> 9199977 | Sep 06, 2033 | DS DP | | | |
| <u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u> | | | | | | |
| A 091664 001 | | | | | >A> PC | Jul 30, 2016 |
| <u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u> | | | | | | |
| A 091664 002 | | | | | >A> PC | Jul 30, 2016 |
| <u>NALOXONE HYDROCHLORIDE - EVZIO</u> | | | | | | |
| N 205787 001 | >A> 9238108 | Jan 22, 2027 | DP | | | |
| <u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u> | | | | | | |
| N 021636 001 | >A> 5840737 | Jul 15, 2016 | U-588 | | | |
| | >A> 6780882 | Jul 15, 2016 | DS DP | | | |
| | >A> 7399772 | Jul 15, 2016 | U-588 | | | |
| <u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u> | | | | | | |
| N 021636 002 | >A> 5840737 | Jul 15, 2016 | U-623 | | | |
| | >A> 5840737 | Jul 15, 2016 | U-624 | | | |
| | >A> 6780882 | Jul 15, 2016 | DS DP | | | |
| | >A> 7399772 | Jul 15, 2016 | U-623 | | | |
| | >A> 7399772 | Jul 15, 2016 | U-624 | | | |
| <u>OSIMERTINIB MESYLATE - TAGRISSO</u> | | | | | | |
| N 208065 001 | | | | | >A> ODE | Nov 13, 2022 |
| <u>OSIMERTINIB MESYLATE - TAGRISSO</u> | | | | | | |
| N 208065 002 | | | | | >A> ODE | Nov 13, 2022 |
| <u>OSPEMIFENE - OSPHENA</u> | | | | | | |
| N 203505 001 | >A> 9241915 | Feb 13, 2024 | U-1369 | | | |
| | >A> 9241915 | Feb 13, 2024 | U-1370 | | | |
| <u>PROPOFOL - PROPOFOL</u> | | | | | | |
| A 205307 001 | | | | | >A> PC | Feb 24, 2016 |
| <u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u> | | | | | | |
| N 205065 001 | >A> 9216178 | Nov 01, 2032 | DP | | | |
| <u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u> | | | | | | |
| N 205065 002 | >A> 7612073 | Nov 17, 2024 | U-1010 | | | |
| | >A> 7612073*PED | May 17, 2025 | | | | |
| | >A> 9216178 | Nov 01, 2032 | DP | | | |
| | >A> RE43797 | Nov 17, 2024 | U-1590 | | | |
| | >A> RE43797*PED | May 17, 2025 | | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 001 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |
| | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 002 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--------------------------------------|-----------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 002 | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 003 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |
| | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 004 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |
| | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 005 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |
| | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 006 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |
| | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 007 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |
| | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 008 | >A> 7205302 | Apr 04, 2023 | DS DP U-1797 | | | |
| | >A> 8791122 | Aug 01, 2030 | DS DP | | | |
| | >A> 9173881 | Aug 12, 2029 | U-1798 | | | |
| <u>SEVELAMER CARBONATE - RENVELA</u> | | | | | | |
| N 022318 001 | >A> 9095509 | Dec 06, 2030 | DP | | | |
| <u>SEVELAMER CARBONATE - RENVELA</u> | | | | | | |
| N 022318 002 | >A> 9095509 | Dec 06, 2030 | DP | | | |
| <u>SUGAMMADEX SODIUM - BRIDION</u> | | | | | | |
| N 022225 001 | >A> 7265099 | Aug 07, 2020 | U-1795 | | | |
| <u>SUGAMMADEX SODIUM - BRIDION</u> | | | | | | |
| N 022225 002 | >A> 7265099 | Aug 07, 2020 | U-1795 | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 001 | >A> 9125816 | Aug 30, 2020 | U-490 | | | |
| | >A> 9125816*PED | Mar 02, 2021 | | | | |
| | >A> 9132089 | Aug 30, 2020 | U-490 | | | |
| | >A> 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 002 | >A> 9125816 | Aug 30, 2020 | U-490 | | | |
| | >A> 9125816*PED | Mar 02, 2021 | | | | |
| | >A> 9132089 | Aug 30, 2020 | U-490 | | | |
| | >A> 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 003 | >A> 9125816 | Aug 30, 2020 | U-490 | | | |
| | >A> 9125816*PED | Mar 02, 2021 | | | | |
| | >A> 9132089 | Aug 30, 2020 | U-490 | | | |
| | >A> 9132089*PED | Mar 02, 2021 | | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 01 - January 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 003 | >A> 9125816 | Aug 30, 2020 | U-490 | | | |
| | >A> 9125816*PED | Mar 02, 2021 | | | | |
| | >A> 9132089 | Aug 30, 2020 | U-490 | | | |
| | >A> 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 022309 001 | >A> 6503894 | Aug 30, 2020 | U-1103 | | | |
| | >A> 6503894*PED | Mar 02, 2021 | | | | |
| | >A> 9125816 | Aug 30, 2020 | U-1103 | | | |
| | >A> 9125816*PED | Mar 02, 2021 | | | | |
| | >A> 9132089 | Aug 30, 2020 | U-1103 | | | |
| | >A> 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 022309 002 | >A> 6503894 | Aug 30, 2020 | U-1103 | | | |
| | >A> 6503894*PED | Mar 02, 2021 | | | | |
| | >A> 9125816 | Aug 30, 2020 | U-1103 | | | |
| | >A> 9125816*PED | Mar 02, 2021 | | | | |
| | >A> 9132089 | Aug 30, 2020 | U-1103 | | | |
| | >A> 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 022309 003 | >A> 6503894 | Aug 30, 2020 | U-1103 | | | |
| | >A> 6503894*PED | Mar 02, 2021 | | | | |
| | >A> 9125816 | Aug 30, 2020 | U-1103 | | | |
| | >A> 9125816*PED | Mar 02, 2021 | | | | |
| | >A> 9132089 | Aug 30, 2020 | U-1103 | | | |
| | >A> 9132089*PED | Mar 02, 2021 | | | | |
| <u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u> | | | | | | |
| N 204114 001 | | | | >A> M-170 | | Nov 20, 2018 |
| <u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u> | | | | | | |
| N 204114 003 | | | | >A> M-170 | | Nov 20, 2018 |
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 001 | >A> 9227946 | Jun 15, 2027 | U-1668 | | | |
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 002 | >A> 9227946 | Jun 15, 2027 | U-1668 | | | |
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 003 | >A> 9227946 | Jun 15, 2027 | U-1668 | | | |
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 004 | >A> 9227946 | Jun 15, 2027 | U-1668 | | | |

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>